<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>a2053544zex-2_1.htm
<DESCRIPTION>EXHIBIT 2.1
<TEXT>

<HTML>
<HEAD>
<TITLE> Prepared by MERRILL CORPORATION
</TITLE>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#01PAL2055_2">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>
<!-- TOC_END -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="kc2055_exhibit_2.1"> </A>
<A NAME="toc_kc2055_1"> </A>
<BR></FONT><FONT SIZE=2><B>EXHIBIT 2.1    <BR>  </B></FONT></P>

<HR NOSHADE>
<HR NOSHADE>
<P ALIGN="CENTER"><FONT SIZE=4><B>AGREEMENT AND PLAN OF MERGER AND REORGANIZATION  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>among:  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=3><B>INHALE THERAPEUTIC SYSTEMS,&nbsp;INC.,<BR>  </B></FONT><FONT SIZE=2><B>a Delaware corporation;  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=3><B>SQUARE ACQUISITION CORP.,<BR>  </B></FONT><FONT SIZE=2><B>an Alabama corporation;  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=3><B>SHEARWATER CORPORATION,<BR>  </B></FONT><FONT SIZE=2><B>an Alabama corporation;  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=3><B>CERTAIN SHAREHOLDERS OF SHEARWATER CORPORATION  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>and  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=3><B>J. MILTON HARRIS,<BR>  </B></FONT><FONT SIZE=2><B>as Shareholders' Agent  </B></FONT></P>

<HR NOSHADE ALIGN="CENTER" WIDTH="120">
<P ALIGN="CENTER"><FONT SIZE=2><B> Dated as of May&nbsp;22, 2001  </B></FONT></P>

<HR NOSHADE ALIGN="CENTER" WIDTH="120">
<HR NOSHADE>
<HR NOSHADE>
<HR NOSHADE>
<!-- ZEQ.=1,SEQ=1,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=723643,FOLIO='blank',FILE='DISK016:[01PAL5.01PAL2055]KC2055A.;8',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<P ALIGN="CENTER"><FONT SIZE=2><B>EXHIBITS  </B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2>Exhibit A</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%" ALIGN="CENTER"><FONT SIZE=2>&#151;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="80%"><FONT SIZE=2>Certain definitions</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
Exhibit B</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="3%" ALIGN="CENTER"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="80%"><FONT SIZE=2><BR>
Directors and officers of Surviving Corporation</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
Exhibit C</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="3%" ALIGN="CENTER"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="80%"><FONT SIZE=2><BR>
Escrow Agreement</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
Exhibit D</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="3%" ALIGN="CENTER"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="80%"><FONT SIZE=2><BR>
Shareholder's Certificate</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
Exhibit E</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="3%" ALIGN="CENTER"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="80%"><FONT SIZE=2><BR>
Forms of tax representation letters</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
Exhibit F</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="3%" ALIGN="CENTER"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="80%"><FONT SIZE=2><BR>
Persons to sign Employment and Noncompetition Agreements</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
Exhibit G</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="3%" ALIGN="CENTER"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="80%"><FONT SIZE=2><BR>
Form of Employment Agreement</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
Exhibit H</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="3%" ALIGN="CENTER"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="80%"><FONT SIZE=2><BR>
Form of Noncompetition Agreement</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
Exhibit I</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="3%" ALIGN="CENTER"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="80%"><FONT SIZE=2><BR>
Lock-Up Agreement</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
Exhibit J</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="3%" ALIGN="CENTER"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="80%"><FONT SIZE=2><BR>
Registration Rights Agreement</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
Exhibit K</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="3%" ALIGN="CENTER"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="80%"><FONT SIZE=2><BR>
Form of Release</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
Exhibit L</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="3%" ALIGN="CENTER"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="80%"><FONT SIZE=2><BR>
Matters to be opined on by Bradley Arant Rose &amp; White LLP</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
Exhibit M</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="3%" ALIGN="CENTER"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="80%"><FONT SIZE=2><BR>
Certain employees</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
Exhibit N</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="3%" ALIGN="CENTER"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="80%"><FONT SIZE=2><BR>
Matters to be opined on by Cooley Godward </FONT><FONT SIZE=2>LLP</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
Exhibit O</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="3%" ALIGN="CENTER"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="80%"><FONT SIZE=2><BR>
Matters to be opined on by Inhale</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
Exhibit P</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="3%" ALIGN="CENTER"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="80%"><FONT SIZE=2><BR>
Letter Agreement by and between the Company and Simon Pedder</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><BR>
Exhibit Q</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="3%" ALIGN="CENTER"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="80%"><FONT SIZE=2><BR>
Form of Cooley Godward </FONT><FONT SIZE=2>LLP</FONT><FONT SIZE=2> tax opinion</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=2,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=686084,FOLIO='blank',FILE='DISK016:[01PAL5.01PAL2055]KD2055A.;8',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<A NAME="page_kd2055_1_1"> </A>
<P ALIGN="CENTER"><FONT SIZE=2><B>TABLE OF CONTENTS  </B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="LEFT"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH WIDTH="76%" ALIGN="LEFT"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="5%" ALIGN="CENTER"><FONT SIZE=1><B>Page</B></FONT><HR NOSHADE></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=4 VALIGN="TOP"><FONT SIZE=2> SECTION 1.&nbsp;&nbsp;DESCRIPTION OF TRANSACTION</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2>1</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
1.1</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Merger of the Company into Merger Sub; Consideration</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
1</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
1.2</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Effect of the Merger</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
1</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
1.3</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Closing; Effective Time</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
1</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
1.4</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Articles of Incorporation and Bylaws; Directors and Officers</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
2</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
1.5</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Conversion of Shares</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
2</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
1.6</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Employee Stock Options</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
3</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
1.7</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Closing of the Company's Transfer Books</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
4</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
1.8</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Exchange of Certificates; Escrow Consideration</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
4</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
1.9</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Dissenting Shares</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
5</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
1.10</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Tax Consequences</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
6</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
1.11</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Accounting Treatment</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
6</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
1.12</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Further Action</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
6</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD COLSPAN=4 VALIGN="TOP"><FONT SIZE=2><BR>
SECTION 2.&nbsp;&nbsp;REPRESENTATIONS AND WARRANTIES OF THE COMPANY AND THE DESIGNATED SHAREHOLDERS</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
6</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
2.1</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Due Organization; No Subsidiaries; Etc.</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
6</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
2.2</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Articles of Incorporation and Bylaws; Records</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
7</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
2.3</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Capitalization, Etc.</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
7</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
2.4</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Financial Statements</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
8</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
2.5</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Absence of Changes</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
9</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
2.6</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Title to Assets</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
10</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
2.7</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Bank Accounts; Receivables</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
10</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
2.8</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Equipment; Real Property and Leasehold</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
11</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
2.9</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Proprietary Assets</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
11</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
2.10</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Contracts</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
12</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
2.11</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Liabilities</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
14</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
2.12</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Compliance with Legal Requirements</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
14</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
2.13</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Governmental Authorizations</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
15</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
2.14</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Tax Matters</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
15</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
2.15</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Employee and Labor Matters; Benefit Plans</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
16</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
2.16</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Environmental Matters</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
18</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
2.17</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Insurance</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
19</FONT></TD>
</TR>
</TABLE>
<!-- insert table folio -->
<P ALIGN="CENTER"><FONT SIZE=2>i</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=3,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=215055,FOLIO='i',FILE='DISK016:[01PAL5.01PAL2055]KD2055A.;8',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<A NAME="page_kd2055_1_2"> </A>
<!-- end of table folio -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
2.18</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Related Party Transactions</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
19</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
2.19</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Legal Proceedings; Orders</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
20</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
2.20</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Authority; Binding Nature of Agreement</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
20</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
2.21</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Non-Contravention; Consents</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
21</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
2.22</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Vote Required</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
21</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
2.23</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Full Disclosure</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
22</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
2.24</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Financial Advisor</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
22</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD COLSPAN=4 VALIGN="TOP"><FONT SIZE=2><BR>
SECTION 3.&nbsp;&nbsp;REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
22</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
3.1</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Due Organization</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
22</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
3.2</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
SEC Filings; Financial Statements</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
22</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
3.3</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Authority; Binding Nature of Agreement</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
23</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
3.4</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Valid Issuance</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
23</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
3.5</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Non-Contravention; Consents</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
23</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
3.6</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Capitalization</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
24</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
3.7</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Absence of Changes</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
24</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
3.8</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Liabilities</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
25</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
3.9</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Legal Proceedings</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
25</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
3.10</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Compliance with Legal Requirements</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
25</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
3.11</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Proprietary Assets</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
25</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD COLSPAN=4 VALIGN="TOP"><FONT SIZE=2><BR>
SECTION 4.&nbsp;&nbsp;CERTAIN COVENANTS OF THE COMPANY AND THE SIGNING SHAREHOLDERS</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
25</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
4.1</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Access and Investigation</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
25</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
4.2</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Operation of the Company's Business</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
25</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
4.3</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Notification; Updates to Disclosure Schedule</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
27</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
4.4</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
No Negotiation</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
28</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=4 VALIGN="TOP"><FONT SIZE=2><BR>
SECTION 5.&nbsp;&nbsp;ADDITIONAL COVENANTS OF THE PARTIES</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
28</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
5.1</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Filings and Consents</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
28</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
5.2</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Sale of Parent Common Stock; Shareholder's Certificates</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
28</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
5.3</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Company Shareholders' Consent</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
29</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
5.4</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Public Announcements</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
29</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
5.5</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Best Efforts</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
29</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
5.6</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Tax Matters</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
29</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
5.7</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Employment and Noncompetition Agreements</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
29</FONT></TD>
</TR>
</TABLE>
<!-- insert table folio -->
<P ALIGN="CENTER"><FONT SIZE=2>ii</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=3,SEQ=4,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=227523,FOLIO='ii',FILE='DISK016:[01PAL5.01PAL2055]KD2055A.;8',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<A NAME="page_kd2055_1_3"> </A>
<!-- end of table folio -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
5.8</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Lock-Up Agreement</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
29</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
5.9</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Employee Related Matters</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
29</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
5.10</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Tax-Free Reorganization</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
30</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
5.11</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
FIRPTA Matters</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
30</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
5.12</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Release</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
30</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
5.13</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Termination of Employee Plans</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
30</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=4 VALIGN="TOP"><FONT SIZE=2><BR>
SECTION 6.&nbsp;&nbsp;CONDITIONS PRECEDENT TO OBLIGATIONS OF PARENT AND MERGER SUB</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
30</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
6.1</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Accuracy of Representations</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
30</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
6.2</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Performance of Covenants</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
31</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
6.3</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Shareholder Approval</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
31</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
6.4</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Consents</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
31</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
6.5</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Agreements and Documents</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
31</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
6.6</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
FIRPTA Compliance</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
32</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
6.7</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Blue Sky Compliance</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
32</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
6.8</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
HSR Act</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
32</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
6.9</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Listing</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
32</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
6.10</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
No Restraints</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
32</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
6.11</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
No Legal Proceedings</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
32</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
6.12</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Employees</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
32</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
6.13</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Termination of Employee Plans</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
32</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
6.14</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Amendment of Real Property Lease</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
32</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
6.15</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Payment of Receivable</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
33</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
6.16</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
No issuance of Capital Stock</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
33</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
6.17</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
No Material Adverse Change</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
33</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=4 VALIGN="TOP"><FONT SIZE=2><BR>
SECTION 7.&nbsp;&nbsp;CONDITIONS PRECEDENT TO OBLIGATIONS OF THE COMPANY</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
33</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
7.1</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Accuracy of Representations</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
33</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
7.2</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Performance of Covenants</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
33</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
7.3</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
No Restraints</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
33</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
7.4</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Consents</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
33</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
7.5</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Agreements and Documents</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
33</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
7.6</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
HSR Act</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
34</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
7.7</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Listing</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
34</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
7.8</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Tax Opinion</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
34</FONT></TD>
</TR>
</TABLE>
<!-- insert table folio -->
<P ALIGN="CENTER"><FONT SIZE=2>iii</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=4,SEQ=5,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=3052,FOLIO='iii',FILE='DISK016:[01PAL5.01PAL2055]KD2055A.;8',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<A NAME="page_kd2055_1_4"> </A>
<!-- end of table folio -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
7.9</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Payment of Consideration</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
34</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD COLSPAN=4 VALIGN="TOP"><FONT SIZE=2><BR>
SECTION 8.&nbsp;&nbsp;TERMINATION</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
34</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
8.1</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Termination Events</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
34</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
8.2</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Termination Procedures</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
35</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
8.3</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Effect of Termination</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
35</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD COLSPAN=4 VALIGN="TOP"><FONT SIZE=2><BR>
SECTION 9.&nbsp;&nbsp;INDEMNIFICATION, ETC.</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
43</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
9.1</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Survival of Representations, Etc.</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
35</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
9.2</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Indemnification by Shareholders</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
35</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
9.3</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
No Contribution</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
37</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
9.4</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Interest</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
37</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
9.5</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Defense of Third Party Claims</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
37</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
9.6</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Exercise of Remedies by Indemnitees Other Than Parent</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
37</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD COLSPAN=4 VALIGN="TOP"><FONT SIZE=2><BR>
SECTION 10.&nbsp;&nbsp;MISCELLANEOUS PROVISIONS</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
38</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
10.1</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Designated Shareholders' Agent</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
38</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
10.2</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Further Assurances</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
38</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
10.3</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Fees and Expenses</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
38</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
10.4</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Attorneys' Fees</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
38</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
10.5</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Notices</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
39</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
10.6</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Confidentiality</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
39</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
10.7</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Time of the Essence</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
40</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
10.8</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Headings</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
40</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
10.9</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Counterparts</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
40</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
10.10</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Governing Law</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
40</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
10.11</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Successors and Assigns</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
40</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
10.12</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Specific Performance</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
40</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
10.13</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Waiver</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
40</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
10.14</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Amendments</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
40</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
10.15</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Severability</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
40</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
10.16</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Parties in Interest</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
41</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
10.17</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Entire Agreement</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
41</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="TOP"><FONT SIZE=2><BR>
10.18</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%" VALIGN="TOP"><FONT SIZE=2><BR>
Construction</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="RIGHT"><FONT SIZE=2><BR>
41</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2>iv</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=5,SEQ=6,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=140311,FOLIO='iv',FILE='DISK016:[01PAL5.01PAL2055]KD2055A.;8',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->

<P><FONT SIZE=2>An
extra section break has been inserted above this paragraph. Do not delete this section break if you plan to add text after the Table of Contents/Authorities. Deleting this break will cause Table of
Contents/Authorities headers and footers to appear on any pages following the Table of Contents/Authorities. </FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=7,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=230136,FOLIO='blank',FILE='DISK016:[01PAL5.01PAL2055]KE2055A.;3',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="page_kg2055_1_1"> </A> </FONT> <FONT SIZE=2><B>AGREEMENT AND PLAN<BR>
OF MERGER AND REORGANIZATION  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>This Agreement and Plan of Merger and Reorganization</B></FONT><FONT SIZE=2> ("Agreement") is made and entered into as of
May&nbsp;22, 2001, by and among: </FONT><FONT SIZE=2><B>Inhale Therapeutic Systems,&nbsp;Inc.</B></FONT><FONT SIZE=2>, a Delaware corporation ("Parent"); </FONT><FONT SIZE=2><B>Square
Acquisition Corp.</B></FONT><FONT SIZE=2>, an Alabama corporation and a wholly owned subsidiary of Parent ("Merger Sub"); </FONT><FONT SIZE=2><B>Shearwater Corporation,</B></FONT><FONT SIZE=2> an
Alabama corporation (the "Company"); </FONT><FONT SIZE=2><B>J. Milton Harris</B></FONT><FONT SIZE=2> as Shareholders' Agent (as defined below) and a Designated Shareholder (as defined below) and </FONT> <FONT SIZE=2><B>Puffinus, L.P.,</B></FONT><FONT
SIZE=2> a Delaware limited partnership (together with J. Milton Harris, the "Designated Shareholders"). The Designated Shareholders are
sometimes referred to in this Agreement as the "Signing Shareholders." Certain other capitalized terms used in this Agreement are defined in Exhibit&nbsp;A. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>Recitals  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>A.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Parent, Merger Sub and the Company intend to effect a merger of the Company into Merger Sub in accordance with this
Agreement and the Alabama Business Corporation Act (the "Merger"). Upon consummation of the Merger, the Company will cease to exist. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>B.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;It is intended that the Merger qualify as a tax-free reorganization within the meaning of
Section&nbsp;368(a) of the Internal Revenue Code of 1986, as amended (the "Code"). For accounting purposes, it is intended that the Merger be treated as a purchase. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>C.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;The Merger and this Agreement each have been approved by the respective boards of directors of Parent, Merger Sub
and the Company. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>D.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;The Designated Shareholders own a total of 829,961 shares of the Common Stock (par value $.01 per share) of the
Company ("Company Common Stock"). Contemporaneously with the execution and delivery of this Agreement, the Signing Shareholders are executing and delivering to Parent a Shareholder Agreement of even
date herewith. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>Agreement  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The parties to this Agreement agree as follows: </FONT></P>

<P><FONT SIZE=2><B>SECTION 1. DESCRIPTION OF TRANSACTION  </B></FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;1.1&nbsp;&nbsp;Merger of the Company into Merger Sub; Consideration.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Upon the terms and subject to the conditions
set forth in this Agreement, at the Effective Time (as defined in Section&nbsp;1.3), the Company shall be merged with and into Merger Sub, and the separate existence of the Company shall cease.
Merger Sub will continue as the surviving corporation in the Merger (the "Surviving Corporation"). Upon the terms and subject to the conditions set forth in this Agreement, as consideration for the
Merger, the Parent shall issue to the shareholders of the Company and holders of Company Options (as defined below) an aggregate of (a)&nbsp;4,000,000 shares (including shares issuable pursuant to
Company Options assumed by Parent as set forth in Section&nbsp;1.6) of Parent Common Stock (the "Stock Consideration") and (b)&nbsp;$72,500,000 in cash (the "Cash Consideration" and collectively
the "Merger Consideration"). </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;1.2&nbsp;&nbsp;Effect of the Merger.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;The Merger shall have the effects set forth in this Agreement and in the
applicable provisions of the Alabama Business Corporation Act. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;1.3&nbsp;&nbsp;Closing; Effective Time.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;The consummation of the transactions contemplated by this Agreement (the
"Closing") shall take place at the offices of Cooley Godward llp, Five Palo Alto Square, Palo Alto, California 94306 at 10:00&nbsp;a.m. at such time and date during the period from the date hereof
through July&nbsp;31, 2001, unless extended by the parties hereto, as Parent and Company may </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=8,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=555964,FOLIO='1',FILE='DISK016:[01PAL5.01PAL2055]KG2055A.;5',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<A NAME="page_kg2055_1_2"> </A>

<P><FONT SIZE=2>
mutually agree, which date shall be no later than the third business day following the satisfaction or waiver of the conditions set forth in Sections 6 and 7 (the "Scheduled Closing Time"). The date
on which the Closing actually takes place is referred to in this Agreement as the "Closing Date." Contemporaneously with the Closing, properly executed articles of merger conforming to the
requirements of the Alabama Business Corporation Act shall be filed with the Secretary of State of the State of Alabama to effect the Merger. The Merger shall become effective at the time such
articles of merger are filed with the Secretary of State of the State of Alabama (the "Effective Time"). </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;1.4&nbsp;&nbsp;Articles of Incorporation and Bylaws; Directors and Officers.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Unless otherwise determined by Parent
and the Company prior to the Effective Time: </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2>&nbsp;the Articles of Incorporation of the Surviving Corporation shall conform to the Articles of Incorporation of Merger
Sub as in effect immediately prior to the Effective Time; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2>&nbsp;the Bylaws of the Surviving Corporation shall conform to the Bylaws of Merger Sub as in effect immediately prior to
the Effective Time; and </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(c)</B></FONT><FONT SIZE=2>&nbsp;the directors and officers of the Surviving Corporation immediately after the Effective Time shall be the
individuals identified on Exhibit&nbsp;B. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;1.5&nbsp;&nbsp;Conversion of Shares.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;</FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2>&nbsp;Subject to Sections 1.8 and 1.9, at the Effective Time, by virtue of the Merger and without any further action on
the part of Parent, Merger Sub, the Company or any shareholder of the Company, each share of Company Common Stock outstanding immediately prior to the Effective Time shall be converted into the right
to receive: (i)&nbsp;the "Applicable Number" (as defined in Section&nbsp;1.5(b)(i)) of shares of the common stock of Parent Common Stock and (ii)&nbsp;the "Applicable Cash Payment" (as defined
in Section&nbsp;1.5(b)(ii)). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2>&nbsp;For purposes of this Agreement: </FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(i)</B></FONT><FONT SIZE=2>&nbsp;The "Applicable Number" shall be the quotient (which number shall not be rounded) obtained by dividing
(A)&nbsp;4,000,000 by (B)&nbsp;the Adjusted Fully Diluted Company Share Amount (as defined in Section&nbsp;1.5(b)(iii)). </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(ii)</B></FONT><FONT SIZE=2>&nbsp;The "Applicable Cash Payment" shall be the quotient (which number shall not be rounded) obtained by dividing
(A)&nbsp;the Cash Consideration by (B)&nbsp;the Adjusted Fully Diluted Company Share Amount. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(iii)</B></FONT><FONT SIZE=2>&nbsp;The "Adjusted Fully Diluted Company Share Amount" shall be the sum of (A)&nbsp;the aggregate number of shares of
Company Common Stock outstanding immediately prior to the Effective Time and (B)&nbsp;the aggregate number of shares of Company Common Stock purchasable under or otherwise subject to all Company
Options outstanding immediately prior to the Effective Time (including all shares of Company Common Stock that may ultimately be purchased under Company Options that are unvested or are otherwise not
then exercisable). </FONT></P>

</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(c)</B></FONT><FONT SIZE=2>&nbsp;Except with respect to (i)&nbsp;the Company's Founding Shareholders Buy Sell Agreement, as amended, and the 1996
Stock Option Plan Shareholders' Buy Sell Agreement, as amended, each of which shall be terminated on or before the Closing Date, (ii)&nbsp;Company Options which accelerate as a result of the
transactions contemplated by this Agreement, and (iii)&nbsp;the repurchase rights provided in the Company's 1996 Nonqualified Stock Option Plan, which rights shall be waived, or eliminated from the
provisions of such plan through an amendment to such plan or other effective action of the Company, if any shares of Company Common Stock outstanding immediately prior to the Effective Time are
unvested or are subject to a repurchase option, risk of forfeiture or other condition under any applicable restricted stock purchase agreement or other agreement with the Company, then the shares of
Parent Common Stock and Applicable Cash Payment issued in exchange for such shares of Company </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=9,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=57841,FOLIO='2',FILE='DISK016:[01PAL5.01PAL2055]KG2055A.;5',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<A NAME="page_kg2055_1_3"> </A>

<P><FONT SIZE=2>
Common Stock will also be unvested and subject to the same repurchase option, risk of forfeiture or other condition. The certificates representing such shares of Parent Common Stock may accordingly be
marked with appropriate legends, and such certificates and the Applicable Cash Payment issued in exchange for such shares, may, at the option of Parent, be held in escrow by Parent until the
repurchase option, risk of forfeiture or other condition shall have lapsed. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(d)</B></FONT><FONT SIZE=2>&nbsp;If, prior to the Effective Time, the outstanding shares of Parent Common Stock shall have been increased, decreased,
changed into or exchanged for a different number or kind of shares or securities as a result of any reorganization, recapitalization, reclassification, stock dividend, stock split, reverse stock
split, or other similar change in capitalization, an appropriate and proportionate adjustment shall be made to the Applicable Number of shares of Parent Common Stock. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;1.6&nbsp;&nbsp;Employee Stock Options.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;At the Effective Time, each stock option that is then outstanding under the
Company's 1996 Nonqualified Stock Option Plan, whether vested or unvested (a "Company Option"), shall be assumed by Parent in accordance with the terms (as in effect as of the date of this Agreement)
of the Company's 1996 Nonqualified Stock Option Plan and the stock option agreement by which such Company Option is evidenced. The term "Company Option" shall not include any options described on
Part&nbsp;1.6 of the Disclosure Schedule. All rights with respect to Company Common Stock under outstanding Company Options shall thereupon be converted into rights with respect to Parent Common
Stock (subject to applicable withholding) in accordance with subsections (a), (b), (c), (d)&nbsp;and (e)&nbsp;of this Section&nbsp;1.6. From and after the Effective Time, (a)&nbsp;each Company
Option assumed by Parent may be exercised solely for shares of Parent Common Stock; (b)&nbsp;the number of shares of Parent Common Stock subject to each such assumed Company Option shall be equal to
the number of shares of Company Common Stock that were subject to such Company Option immediately prior to the Effective Time multiplied by the Applicable Number, rounded down to the nearest whole
number of shares of Parent Common Stock; (c)&nbsp;the per share exercise price for the Parent Common Stock issuable upon exercise of each such assumed Company Option shall be determined by dividing
the exercise price per share of Company Common Stock subject to such Company Option, as in effect immediately prior to the Effective Time, by the Applicable Number, and rounding the resulting exercise
price up to the nearest whole cent; (d)&nbsp;except as set forth in subsection (e)&nbsp;below or as may result from the consummation of the transactions contemplated by this Agreement, all
restrictions on the exercise of each such assumed Company Option shall continue in full force and effect, and the term, exercisability, and other
provisions of such Company Option shall otherwise remain unchanged; and (e)&nbsp;the Company's 1996 Nonqualified Stock Option Plan shall be amended, the applicable provisions waived or such other
necessary action of the Company taken, to (i)&nbsp;clarify the rights of Parent, including under Section&nbsp;5.3 of such Plan, to assume the Company's Options in accordance with this Agreement
and upon the occurrence of certain corporate transactions; (ii)&nbsp;eliminate the Company's repurchase rights with respect to the Company's Options set forth in Section&nbsp;6.9 of such Plan and
the Company Common Stock issuable upon exercise of such Company Options under Article&nbsp;VII of such Plan; (iii)&nbsp;provide for a 90-day period after termination of employment,
engagement and directorship, as the case may be, to exercise the Company Options; (iv)&nbsp;eliminate the provisions of Section&nbsp;9.2 of such Plan (to the extent the ongoing effect of such
provision would have an adverse effect on the holders of Company Options); and (v)&nbsp;make other conforming amendments as agreed upon by the Parent and the Company; </FONT> <FONT SIZE=2><I>provided, however,</I></FONT><FONT SIZE=2> that, except for
the Company Options listed on Part&nbsp;1.6 of the Disclosure Schedule, all such Company Options shall immediately
vest and become exercisable at the Effective Time; and </FONT><FONT SIZE=2><I>provided, further, however,</I></FONT><FONT SIZE=2> that each such assumed Company Option shall, in accordance with its
terms, be subject to further adjustment as appropriate to reflect any stock split, reverse stock split, stock dividend, recapitalization or other similar transaction effected by Parent after the
Effective Time. In addition, as of the Effective Time, each holder of an assumed Company Option shall be entitled to receive a cash payment equal to the product of the Applicable Cash Payment and the
number of shares of Company Common Stock that were subject to such assumed Company Option immediately prior to the Effective Time (the "Company Option Cash Payment"), subject to applicable </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=3,SEQ=10,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=898189,FOLIO='3',FILE='DISK016:[01PAL5.01PAL2055]KG2055A.;5',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<A NAME="page_kg2055_1_4"> </A>

<P><FONT SIZE=2>
withholding. The Company and Parent shall take all action that may be necessary (under the Company's 1996 Nonqualified Stock Option Plan and otherwise) to effectuate the provisions of this
Section&nbsp;1.6. Following the Closing, Parent will send or deliver to each holder of an assumed Company Option (A)&nbsp;a written notice setting forth (i)&nbsp;the number of shares of Parent
Common Stock subject to such assumed Company Option, and (ii)&nbsp;the exercise price per share of Parent Common Stock issuable upon exercise of such assumed Company Option, and (B)&nbsp;the
applicable Company Option Cash Payment. Parent shall file with the SEC, not later than the earlier of (y)&nbsp;forty-five (45)&nbsp;days following the Closing Date, or (z)&nbsp;five
(5)&nbsp;days following the filing of any current report on Form&nbsp;8-K required to be filed by Parent after the Closing with respect to the transactions contemplated herein (which
report shall include all financial statements required to be included in such report), a registration statement on Form&nbsp;S-8 (or any successor or appropriate form) registering the
exercise of the Company Options assumed by Parent pursuant to this Section&nbsp;1.6 and shall use its reasonable best efforts to maintain the effectiveness of such registration statement, including
the prospectus or prospectuses contained therein, for so long as such Company Options remain outstanding. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;1.7&nbsp;&nbsp;Closing of the Company's Transfer Books.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;At the Effective Time, holders of certificates
representing shares of the Company's capital stock that were outstanding immediately prior to the Effective Time shall cease to have any rights as shareholders of the Company, and the stock transfer
books of the Company shall be closed with respect to all shares of such capital stock outstanding immediately prior to the Effective Time. No further transfer of any such shares of the Company's
capital stock shall be made on such stock transfer books after the Effective Time. If, after the Effective Time, a valid certificate previously representing any of such shares of the Company's capital
stock (a "Company Stock Certificate") is presented to the Surviving Corporation or Parent, such Company Stock Certificate shall be canceled and shall be exchanged as provided in Section&nbsp;1.8. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;1.8&nbsp;&nbsp;Exchange of Certificates; Escrow Consideration</B></FONT><FONT SIZE=2>.&nbsp;&nbsp;</FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2>&nbsp;On or before the Effective Time, Parent will deposit that portion of the Cash Consideration payable with respect to
the outstanding shares of Company Common Stock with the Escrow Agent who shall have received instructions with respect to distribution in accordance with the Escrow Agreement (as defined below).
Within five (5)&nbsp;days prior to the Effective Time, Parent will send to the holders of Company Stock Certificates (i)&nbsp;a letter of transmittal in customary form and containing such
provisions as Parent may reasonably specify, and (ii)&nbsp;instructions for use in effecting the surrender of Company Stock Certificates in exchange for (A)&nbsp;certificates representing Parent
Common Stock and (B)&nbsp;the appropriate cash payment. Upon surrender of a Company Stock Certificate to the Escrow Agent for exchange, together with a duly executed letter of transmittal and such
other documents as may be reasonably required by the Escrow Agent or the Company's Transfer Agent, the holder of such Company Stock Certificate shall receive in exchange therefor: (i)&nbsp;a
certificate representing the number of whole shares of Parent Common Stock that such holder has the right to receive pursuant to the provisions of Section&nbsp;1.5 after giving effect to the
Escrowed Shares (as defined below); (ii)&nbsp;a cash payment, made by the Escrow Agent to the record owner of such Company Stock Certificate, in an amount equal to the cash payment such holder has a
right to receive pursuant to the provisions of Section&nbsp;1.5 after giving effect to the Escrowed Cash (as defined below); and the Company Stock Certificate so surrendered shall be canceled. The
parties have determined to establish an escrow of a portion of the Merger Consideration having a value as of the Effective Time of $12,000,000.00 (the "Escrow Consideration") and which is comprised of
(i)&nbsp;that portion of the Cash Consideration having a value equal to the product of (A)&nbsp;the Escrow Consideration and the (B)&nbsp;the quotient obtained by dividing the value of the
aggregate Cash Consideration by the value of the Merger Consideration on the date prior to the Closing Date (valuing the Parent Common Stock at the Parent Stock Price (the "Escrowed Cash") and
(ii)&nbsp;that portion of the Stock Consideration having a value equal to the product of (A)&nbsp;the Escrow Consideration and the (B)&nbsp;the quotient obtained by dividing the value of the
aggregate Stock Consideration on the date prior to the Closing Date (valuing the Parent Common </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=4,SEQ=11,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=810958,FOLIO='4',FILE='DISK016:[01PAL5.01PAL2055]KG2055A.;5',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<A NAME="page_kg2055_1_5"> </A>

<P><FONT SIZE=2>
Stock at the Parent Stock Price) by the value of the Merger Consideration on the date prior to the Closing Date (valuing the Parent Common Stock at the Parent Stock Price) (the "Escrowed Shares"). As
soon as practicable after the Effective Time, Parent shall deliver to the Escrow Agent, on behalf and in the name of each Company shareholder, a certificate representing the Escrowed Shares. The
Escrow Consideration shall be held by the Escrow Agent under the terms of the Escrow Agreement substantially in the form of Exhibit&nbsp;C hereto (as such form may be reasonably amended at the
request of the Escrow Agent) for the purposes of funding any indemnification obligations that may arise under or be incurred by the shareholders of the Company pursuant to Section&nbsp;9 hereof.
Until surrendered as contemplated by this Section&nbsp;1.8, each Company Stock Certificate shall be deemed, from and after the Effective Time, to represent only the right to receive upon such
surrender: (i)&nbsp;a certificate representing shares of Parent Common Stock (and cash in lieu of any fractional share of Parent Common Stock) as contemplated by this Section&nbsp;1; and
(ii)&nbsp;a cash payment as contemplated by this Section&nbsp;1. If any Company Stock Certificate shall have been lost, stolen or destroyed, Parent may, in its discretion and as a condition
precedent to the issuance of: (i)&nbsp;any certificate representing Parent Common Stock; or (ii)&nbsp;any cash payment, require the owner of such lost, stolen or destroyed Company Stock
Certificate to provide an appropriate affidavit and to deliver a bond (in such sum as Parent may reasonably direct) as indemnity against any claim that may be made against Parent or the Surviving
Corporation with respect to such Company Stock Certificate. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2>&nbsp;No dividends or other distributions declared or made with respect to Parent Common Stock with a record date after
the Effective Time shall be paid to the holder of any unsurrendered Company Stock Certificate with respect to the shares of Parent Common Stock represented thereby, and no cash payment due pursuant to
Section&nbsp;1.5 or in lieu of any fractional share shall be paid to any such holder, until such holder surrenders such Company Stock Certificate in accordance with this Section&nbsp;1.8 (at which
time such holder shall be entitled to receive all such dividends and distributions and such cash payment). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(c)</B></FONT><FONT SIZE=2>&nbsp;No fractional shares of Parent Common Stock shall be issued in connection with the Merger, and no certificates for
any such fractional shares shall be issued. In lieu of such fractional shares, any holder of capital stock of the Company who would otherwise be entitled to receive a fraction of a share of Parent
Common Stock (after aggregating all fractional shares of Parent Common Stock issuable to such holder) shall, upon surrender of such holder's Company Stock Certificate(s), be paid in cash the dollar
amount (rounded to the nearest whole cent), without interest, determined by multiplying such fraction by the Parent Stock Price. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(d)</B></FONT><FONT SIZE=2>&nbsp;Parent and the Surviving Corporation shall be entitled to deduct and withhold from any consideration payable or
otherwise deliverable to any holder or former holder of capital stock of the Company or Company Option pursuant to this Agreement such amounts as Parent or the Surviving Corporation may be required to
deduct or withhold therefrom under the Code or under any provision of state, local or foreign tax law. To the extent such amounts are so deducted or withheld, such amounts shall be treated for all
purposes under this Agreement as having been paid to the Person to whom such amounts would otherwise have been paid. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(e)</B></FONT><FONT SIZE=2>&nbsp;Neither Parent nor the Surviving Corporation shall be liable to any holder or former holder of capital stock of the
Company or Company Option for any shares of Parent Common Stock (or dividends or distributions with respect thereto), or for any cash amounts, delivered to any public official pursuant to any
applicable abandoned property, escheat or similar law. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;1.9&nbsp;&nbsp;Dissenting Shares</B></FONT><FONT SIZE=2>.&nbsp;&nbsp;</FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2>&nbsp;Notwithstanding anything to the contrary contained in this Agreement, any shares of capital stock of the Company
that, as of the Effective Time, are held by any Person who is entitled to demand and properly notifies the Company of such Person's intent to demand payment of the fair value of the shares held by
such Person pursuant to, and who has complied in all respects with Article&nbsp;13 of the </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=5,SEQ=12,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=132714,FOLIO='5',FILE='DISK016:[01PAL5.01PAL2055]KG2055B.;6',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<A NAME="page_kg2055_1_6"> </A>

<P><FONT SIZE=2>
Alabama Business Corporation Act to the extent such compliance is required prior to the Effective Time ("Dissenting Shares"), shall not be converted into or represent the right to receive:
(i)&nbsp;Parent Common Stock in accordance with Section&nbsp;1.5, or (ii)&nbsp;any cash payment in accordance with Section&nbsp;1.5 (or cash in lieu of fractional shares in accordance with
Section&nbsp;1.8(c)), and the holder or holders of such shares shall be entitled only to such rights as may be granted to such holder or holders in Article&nbsp;13 of the Alabama Business
Corporation Act; </FONT><FONT SIZE=2><I>provided, however,</I></FONT><FONT SIZE=2> that if any such holder shall fail to perfect or otherwise shall waive, withdraw or lose the right to receive
payment of the fair value of such holder's Dissenting Shares pursuant to Article&nbsp;13 of the Alabama Business Corporations Act, then the rights of such holder to be paid the fair value of such
holder's Dissenting Shares shall cease, and such Dissenting Shares shall automatically be converted into and shall represent only the right to receive (upon the surrender of the certificate or
certificates representing such shares) (i)&nbsp;Parent Common Stock in accordance with Section&nbsp;1.5, and (ii)&nbsp;the appropriate cash payment in accordance with Section&nbsp;1.5 (and
cash in lieu of fractional shares in accordance with Section&nbsp;1.8(c)). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2>&nbsp;The Company shall give Parent (i)&nbsp;prompt notice of any written demand received by the Company prior to the
Effective Time to require the Company to pay fair value of any shares of capital stock of the Company pursuant to Article&nbsp;13 of the Alabama Business Corporation Act and of any other demand,
notice or instrument delivered to the Company prior to the Effective Time pursuant to the Alabama Business Corporation Act, and (ii)&nbsp;the opportunity to participate in all negotiations and
proceedings with respect to any such demand, notice or instrument. The Company shall not make any payment or settlement offer prior to the Effective Time with respect to any such demand unless Parent
shall have consented in writing to such payment or settlement offer. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;1.10&nbsp;&nbsp;Tax Consequences.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;For federal income tax purposes, the Merger is intended to constitute a
reorganization within the meaning of Section&nbsp;368 of the Code. The parties to this Agreement hereby adopt this Agreement as a "plan of reorganization" within the meaning of Sections
1.368-2(g) and 1.368-3(a) of the United States Treasury Regulations. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;1.11&nbsp;&nbsp;Accounting Treatment.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;For accounting purposes, the Merger is intended to be treated as a purchase. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;1.12&nbsp;&nbsp;Further Action.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;If, at any time after the Effective Time, any further action is determined by
Parent to be necessary or desirable to carry out the purposes of this Agreement or to vest the Surviving Corporation or Parent with full right, title and possession of and to all rights and property
of Merger Sub and the Company, the officers and directors of the Surviving Corporation and Parent shall be fully authorized (in the name of Merger Sub, in the name of the Company and otherwise) to
take such action. </FONT></P>

<P><FONT SIZE=2><B>SECTION 2. REPRESENTATIONS AND WARRANTIES OF THE COMPANY AND THE DESIGNATED SHAREHOLDERS  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Company and the Designated Shareholders jointly and severally represent and warrant, to and for the benefit of the Indemnitees, as follows: </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;2.1&nbsp;&nbsp;Due Organization; No Subsidiaries; Etc.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;</FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2>&nbsp;The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of
Alabama and has all necessary corporate power and authority: (i)&nbsp;to conduct its business in the manner in which its business is currently being conducted; (ii)&nbsp;to own and use its assets
in the manner in which its assets are currently owned and used; and (iii)&nbsp;to perform its obligations under all Company Contracts. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2>&nbsp;Except as set forth in Part&nbsp;2.1 of the Disclosure Schedule, the Company has not conducted any business under
or otherwise used, for any purpose or in any jurisdiction, any fictitious name, assumed name, trade name or other name, other than the name "Shearwater Corporation." </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=6,SEQ=13,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=764296,FOLIO='6',FILE='DISK016:[01PAL5.01PAL2055]KG2055B.;6',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<A NAME="page_kg2055_1_7"> </A>

<P><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>(c)</B></FONT><FONT SIZE=2>&nbsp;The Company is not and has not been required to be qualified, authorized, registered or licensed to do business as a
foreign corporation in any jurisdiction other than the jurisdictions identified in Part&nbsp;2.1 of the Disclosure Schedule, except where the failure to be so qualified, authorized, registered or
licensed has not had and will not have a Material Adverse Effect on the Company. The Company is in good standing as a foreign corporation in each of the jurisdictions identified in Part&nbsp;2.1 of
the Disclosure Schedule. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(d)</B></FONT><FONT SIZE=2>&nbsp;Part&nbsp;2.1 of the Disclosure Schedule accurately sets forth (i)&nbsp;the names of the members of the
Company's board of directors, (ii)&nbsp;the names of the members of each committee of the Company's board of directors, and (iii)&nbsp;the names and titles of the Company's officers. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(e)</B></FONT><FONT SIZE=2>&nbsp;The Company does not own any controlling interest in any Entity and, except for the equity interests identified in
Part&nbsp;2.1 of the Disclosure Schedule, since December&nbsp;31, 1999, the Company has not owned, beneficially or otherwise, any shares or other securities of, or any direct or indirect equity
interest in, any Entity (except to the extent that any of the Company Contracts could be construed as an indirect interest in any Entity). Except as set forth on Part&nbsp;2.1 of the Disclosure
Schedule, the Company has not agreed and is not obligated to make any future investment in or capital contribution to any Entity
(except to the extent that any of the Company Contracts could be construed as an indirect interest in any Entity). Except as set forth on Part&nbsp;2.1 of the disclosure Schedule the Company has not
guaranteed and is not responsible or liable for any obligation of any of the Entities in which it owns or has owned any equity interest (except to the extent that any of the Company Contracts could be
construed as an indirect interest in any Entity). </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;2.2&nbsp;&nbsp;Articles of Incorporation and Bylaws; Records.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;The Company has delivered to Parent accurate and
complete copies of: (1)&nbsp;the Company's articles of incorporation and bylaws, including all amendments thereto; (2)&nbsp;the stock records of the Company; and (3)&nbsp;except as set forth in
Part&nbsp;2.2 of the Disclosure Schedule, the minutes and other records of the meetings and other proceedings (including any actions taken by written consent or otherwise without a meeting) of the
shareholders of the Company, the board of directors of the Company and all committees of the board of directors of the Company. There have been no formal meetings or other proceedings of the
shareholders of the Company, the board of directors of the Company or any committee of the board of directors of the Company that are not in all material respects reflected in such minutes or other
records. There has not been any violation of any of the provisions of the Company's articles of incorporation or bylaws, and the Company has not taken any action that is inconsistent in any material
respect with any resolution adopted by the Company's shareholders, the Company's board of directors or any committee of the Company's board of directors that could reasonably be expected to have a
Material Adverse Effect on the Company. The books of account, stock records, minute books and other records of the Company are accurate, up-to-date and complete in all material
respects, and have been maintained in accordance with prudent business practices. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;2.3&nbsp;&nbsp;Capitalization, Etc.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;</FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2>&nbsp;The authorized capital stock of the Company consists of 2,000,000 shares of Common Stock, par value $0.01 per share,
of which 1,008,563 shares have been issued and are outstanding as of the date of this Agreement. All of the outstanding shares of Company Common Stock have been duly authorized and validly issued, and
are fully paid and non-assessable. Part&nbsp;2.3 of the Disclosure Schedule lists each agreement pursuant to which the Company holds a repurchase option and to which any of such shares
is subject. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2>&nbsp;The Company has reserved 300,000 shares of Company Common Stock for issuance under its 1996 Nonqualified Stock
Option Plan, of which options to purchase 289,446 shares are outstanding (not including any options which may have been or will be granted as described on Part&nbsp;1.6 of the Disclosure Schedule)
as of the date of this Agreement. Part&nbsp;2.3 of the Disclosure Schedule accurately sets forth, with respect to each Company Option that is outstanding as of the date of this Agreement: </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=7,SEQ=14,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=595459,FOLIO='7',FILE='DISK016:[01PAL5.01PAL2055]KG2055B.;6',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<A NAME="page_kg2055_1_8"> </A>

<P><FONT SIZE=2>
(i)&nbsp;the name of the holder of such Company Option; (ii)&nbsp;the total number of shares of Company Common Stock that are subject to such Company Option and the number of shares of Company
Common Stock with respect to which such Company Option is immediately exercisable; (iii)&nbsp;the date on
which such Company Option was granted and the term of such Company Option; (iv)&nbsp;the vesting schedule for such Company Option; and (v)&nbsp;the exercise price per share of Company Common Stock
purchasable under such Company Option. None of the Company Options have been designated an "incentive stock option" as defined in Section&nbsp;422 of the Code. Except as set forth in Part&nbsp;2.3
of the Disclosure Schedule, there is no: (i)&nbsp;outstanding subscription, option, call, warrant or right (whether or not currently exercisable) to acquire any shares of the capital stock or other
securities of the Company; (ii)&nbsp;outstanding security, instrument or obligation that is or may become convertible into or exchangeable for any shares of the capital stock or other securities of
the Company; (iii)&nbsp;Contract under which the Company is or may become obligated to sell or otherwise issue any shares of its capital stock or any other securities; or (iv)&nbsp;to the best of
the knowledge of the Company and the Designated Shareholders, condition or circumstance that may give rise to or provide a basis for the assertion of a claim by any Person to the effect that such
Person is entitled to acquire or receive any shares of capital stock or other securities of the Company. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(c)</B></FONT><FONT SIZE=2>&nbsp;All outstanding shares of Company Common Stock and all outstanding Company Options, have been issued and granted in
compliance with (i)&nbsp;all applicable securities laws and other applicable Legal Requirements, and (ii)&nbsp;all material requirements set forth in applicable Contracts. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(d)</B></FONT><FONT SIZE=2>&nbsp;Except as set forth in Part&nbsp;2.3 of the Disclosure Schedule, the Company has never repurchased, redeemed or
otherwise reacquired any shares of capital stock or other securities of the Company. All securities so reacquired by the Company were reacquired in compliance with (i)&nbsp;the applicable provisions
of the Alabama Business Corporation Act and all other applicable Legal Requirements, and (ii)&nbsp;all material requirements set forth in applicable restricted stock purchase agreements and other
applicable Contracts. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;2.4&nbsp;&nbsp;Financial Statements</B></FONT><FONT SIZE=2>.&nbsp;&nbsp;</FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2>&nbsp;The Company has delivered to Parent the following financial statements and notes (collectively, the "Company
Financial Statements"): </FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(i)</B></FONT><FONT SIZE=2>&nbsp;The audited balance sheet of the Company as of June&nbsp;30, 2000, and the related audited income statement,
statement of shareholders' equity and statement of cash flows of the Company for the year then ended, together with the notes thereto and the unqualified report and opinion of Ernst&nbsp;&amp; Young,
LLP relating thereto; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(ii)</B></FONT><FONT SIZE=2>&nbsp;The unaudited balance sheet of the Company as of June&nbsp;30, 1999, and the related unaudited income statement,
statement of shareholders' equity, and statement of cash flows of the Company for the year then ended; and </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(iii)</B></FONT><FONT SIZE=2>&nbsp;the unaudited balance sheet of the Company as of March&nbsp;31, 2001 (the "Unaudited Interim Balance Sheet"),
and the related unaudited income statement of the Company for the nine months then ended. </FONT></P>

</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2>&nbsp;Except as set forth in Part&nbsp;2.4 of the Disclosure Schedule, the Company Financial Statements fairly present
the financial position of the Company as of the respective dates thereof and the results of operations and (in the case of the financial statements referred to in Section&nbsp;2.4(a)(i)&nbsp;and
2.4(a)(ii)) cash flows of the Company for the periods covered thereby. The Company Financial Statements have been prepared in accordance with generally accepted accounting principles applied on a
consistent basis throughout the periods covered (except that the financial statements referred to in Section&nbsp;2.4(a)(iii)&nbsp;do not contain footnotes and are subject to normal and recurring
year-end audit adjustments, which, except as set forth on part&nbsp;2.4 of the Disclosure Schedule, will not, individually or in the aggregate, be material in magnitude). </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=8,SEQ=15,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=541050,FOLIO='8',FILE='DISK016:[01PAL5.01PAL2055]KG2055B.;6',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->

<P><FONT SIZE=2><A
NAME="page_ki2055_1_9"> </A> </FONT> <FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;2.5&nbsp;&nbsp;Absence of Changes.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Except as set forth in Part&nbsp;2.5 of the Disclosure Schedule, since
March&nbsp;31, 2001: </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2>&nbsp;there has not been any material adverse change in the Company's business, condition, assets, liabilities,
operations, results of operations of the Company taken as whole, and, to the knowledge of the Company and the Designated Shareholders, no event has occurred that will, or could reasonably be expected
to, have a Material Adverse Effect on the Company; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2>&nbsp;there has not been any material loss, damage or destruction to, or any material interruption in the use of, any of
the Company's assets (whether or not covered by insurance); </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(c)</B></FONT><FONT SIZE=2>&nbsp;the Company has not declared, accrued, set aside or paid any dividend or made any other distribution in respect of
any shares of capital stock, and has not repurchased, redeemed or otherwise reacquired any shares of capital stock or other securities; </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(d)</B></FONT><FONT SIZE=2>&nbsp;the Company has not sold, issued or authorized the issuance of (i)&nbsp;any capital stock or other security
(except for Company Common Stock issued upon the exercise of outstanding Company Options), (ii)&nbsp;any option or right to acquire any capital stock or any other security (except for Company
Options described in Part&nbsp;2.3 of the Disclosure Schedule), or (iii)&nbsp;any instrument convertible into or exchangeable for any capital stock or other security(except for Company Options
described in Part&nbsp;2.3 of the Disclosure Schedule); </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(e)</B></FONT><FONT SIZE=2>&nbsp;the Company has not amended or waived any of its rights under, or permitted the acceleration of vesting under
(except to the extent that this transaction would cause such an acceleration or as otherwise contemplated by this Agreement), (i)&nbsp;any provision of its 1996 Nonqualified Stock Option Plan,
(ii)&nbsp;any provision of any agreement evidencing any outstanding Company Option, or (iii)&nbsp;any restricted stock purchase agreement; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(f)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;there has been no amendment to the Company's articles of incorporation or bylaws, and the Company has not effected
or been a party to any Acquisition Transaction, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction; </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(g)</B></FONT><FONT SIZE=2>&nbsp;the Company has not formed any subsidiary or acquired any equity interest or other interest in any other Entity
(except to the extent that any Company Contract could be construed as an indirect interest in any Entity); </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(h)</B></FONT><FONT SIZE=2>&nbsp;the Company has not made any capital expenditure which, when added to all other capital expenditures made on behalf
of the Company since March&nbsp;31, 2001, exceeds $100,000. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(i)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;the Company has not (i)&nbsp;entered into or permitted any of the assets owned or used by it to become bound by
any Contract that is or would constitute a Material Contract (as defined in Section&nbsp;2.10(a)), or (ii)&nbsp;amended or prematurely terminated, or waived any material right or remedy under, any
such Contract; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(j)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;the Company has not (i)&nbsp;acquired, leased or licensed any right or other asset from any other Person,
(ii)&nbsp;sold or otherwise disposed of, or leased or licensed, any right or other asset to any other Person, or (iii)&nbsp;waived or relinquished any right, except for immaterial rights or other
immaterial assets acquired, leased, licensed or disposed of in the ordinary course of business and consistent with the Company's past practices; </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(k)</B></FONT><FONT SIZE=2>&nbsp;the Company has not written off as uncollectible, or established any extraordinary reserve with respect to, any
account receivable or other indebtedness; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(l)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;the Company has not made any pledge of any of its assets or otherwise permitted any of its assets to become subject
to any Encumbrance, except for pledges of immaterial assets made in the ordinary course of business and consistent with the Company's past practices; </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=16,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=139524,FOLIO='9',FILE='DISK016:[01PAL5.01PAL2055]KI2055A.;7',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<A NAME="page_ki2055_1_10"> </A>

<P><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>(m)</B></FONT><FONT SIZE=2>&nbsp;the Company has not (i)&nbsp;lent money to any Person (other than pursuant to routine travel advances made to
employees in the ordinary course of business), or (ii)&nbsp;incurred or guaranteed any indebtedness for borrowed money; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(n)</B></FONT><FONT SIZE=2>&nbsp;the Company has not (i)&nbsp;established or adopted any Employee Benefit Plan, (ii)&nbsp;paid any bonus or made
any profit-sharing or similar payment to, or increased the amount of the wages, salary, commissions, fringe benefits or other compensation or remuneration payable to, any of its directors, officers or
employees other than bonuses and raises paid in the ordinary course of business and consistent with past practice that do not exceed $5,000 individually or $100,000 in the aggregate, or
(iii)&nbsp;hired any new employee with an expected aggregate annual compensation in excess of $40,000; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(o)</B></FONT><FONT SIZE=2>&nbsp;the Company has not changed any of its methods of accounting or accounting practices; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(p)</B></FONT><FONT SIZE=2>&nbsp;the Company has not made any Tax election (except to the extent the filing of the Company's Tax returns in the
ordinary course of business constitutes a Tax election); </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(q)</B></FONT><FONT SIZE=2>&nbsp;the Company has not commenced or settled any Legal Proceeding; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(r)</B></FONT><FONT SIZE=2>&nbsp;the Company has not entered into any material transaction or taken any other material action outside the ordinary
course of business or otherwise inconsistent with its past practices; and </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(s)</B></FONT><FONT SIZE=2>&nbsp;the Company has not agreed or committed to take any of the actions referred to in clauses "(c)" through "(r)" above. </FONT></P>


<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;2.6&nbsp;&nbsp;Title to Assets</B></FONT><FONT SIZE=2>.&nbsp;&nbsp;</FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2>&nbsp;The Company owns, and has good, valid and marketable title to, all real property and tangible personal property
(other than Proprietary Assets) purported to be owned by it, including: (i)&nbsp;all real property and tangible personal property reflected on the Unaudited Interim Balance Sheet; and
(ii)&nbsp;all other real property and tangible personal property (other than Proprietary Assets) reflected in the Company's books and records as being owned by the Company. Except as set forth in
Part&nbsp;2.6 of the Disclosure Schedule, all of said real property and tangible personal property (other than Proprietary Assets) are owned by the Company free and clear of any liens or other
Encumbrances, except for (i)&nbsp;any lien for current taxes not yet due and payable, and (ii)&nbsp;minor liens that have arisen in the ordinary course of business and that do not (in any case or
in the aggregate) materially detract from the value of the real property and tangible personal property (other than Proprietary Assets) subject thereto or materially impair the operations of the
Company. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2>&nbsp;Part&nbsp;2.6 of the Disclosure Schedule identifies all real property and tangible personal property (other than
Proprietary Assets) that are material to the business of the Company and that are being leased or licensed to the Company. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;2.7&nbsp;&nbsp;Bank Accounts; Receivables</B></FONT><FONT SIZE=2>.&nbsp;&nbsp;</FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2>&nbsp;Part&nbsp;2.7(a) of the Disclosure Schedule accurately sets forth the account number, bank or financial
institution, authorized signators and account balance (as of the business day immediately prior to the date of this Agreement) with respect to each account maintained by or for the benefit of the
Company
at any bank or other financial institution, and identifies the securities or other interests held in such accounts (as of the business day immediately prior to the date of the Agreement). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2>&nbsp;Part&nbsp;2.7(b) of the Disclosure Schedule accurately sets forth a breakdown and aging of all accounts
receivable, notes receivable and other receivables of the Company as of March&nbsp;31, 2001. Except as set forth in Part&nbsp;2.7(b) of the Disclosure Schedule, all existing accounts receivable of
the Company (including those accounts receivable reflected on the Unaudited Interim Balance Sheet that have not yet been collected and those accounts receivable that have arisen since March&nbsp;31,
2001, and have not yet been collected) (i)&nbsp;represent valid obligations of customers of the Company arising from bona fide transactions entered into in the ordinary course of business,
(ii)&nbsp;are current and will be </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=17,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=367540,FOLIO='10',FILE='DISK016:[01PAL5.01PAL2055]KI2055A.;7',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<A NAME="page_ki2055_1_11"> </A>


<P><FONT SIZE=2>
collected in full, without any counterclaim or set off (net of an allowance for doubtful accounts not to exceed $100,000 in the aggregate). </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;2.8&nbsp;&nbsp;Equipment; Real Property and Leasehold</B></FONT><FONT SIZE=2>.&nbsp;&nbsp;</FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2>&nbsp;All material items of equipment and other material tangible assets owned by or leased to the Company are adequate
for the uses to which they are being put, are in good condition and repair (ordinary wear and tear excepted) and are adequate for the conduct of the Company's business in the manner in which such
business is currently being conducted. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2>&nbsp;The Company does not own any real property or any interest in real property, except for the real property and
leasehold interests created under the real property leases identified in Part&nbsp;2.10 of the Disclosure Schedule. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;2.9&nbsp;&nbsp;Proprietary Assets</B></FONT><FONT SIZE=2>.&nbsp;&nbsp;</FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2>&nbsp;Part&nbsp;2.9(a)(i)&nbsp;of the Disclosure Schedule sets forth, with respect to each Proprietary Asset owned by
the Company and registered with any Governmental Body or for which an application has been filed with any Governmental Body, (i)&nbsp;a brief description of such Proprietary Asset, and
(ii)&nbsp;the names of the jurisdictions covered by the applicable registration or application. Part&nbsp;2.9(a)(ii)&nbsp;of the Disclosure Schedule identifies and provides a brief description
of each other material Proprietary Asset owned by the Company necessary to conduct the business of the Company as currently conducted to the extent that the Company maintains written documentation of
such Proprietary Assets. Part&nbsp;2.9(a)(iii)&nbsp;of the Disclosure Schedule identifies each Contract containing any ongoing royalty or payment obligations in excess of $10,000 annually with
respect to each Proprietary Asset that is licensed or otherwise made available to the Company by any Person (except for any Proprietary Asset that is licensed to the Company under any third party
software license generally available to the public at a cost of less than $5,000). Except as set forth in Part&nbsp;2.9(c) of the Disclosure Schedule, the Company owns all of the
Company Proprietary Assets identified or required to be identified in Parts 2.9(a)(i)&nbsp;and 2.9(a)(ii)&nbsp;of the Disclosure Schedule, free and clear of all Encumbrances, except for
(i)&nbsp;any lien for current taxes not yet due and payable, and (ii)&nbsp;minor liens that have arisen in the ordinary course of business and that do not (individually or in the aggregate)
materially detract from the value of the Company Proprietary Assets subject thereto or materially impair the operations of the Company. To the knowledge of the Company, and the Designated
Shareholders, the Company has a valid right to use, license and otherwise exploit all Proprietary Assets identified in Part&nbsp;2.9(a)(iii)&nbsp;of the Disclosure Schedule. Except as set forth in
Part&nbsp;2.9(a)(iv)&nbsp;of the Disclosure Schedule, the Company has not developed jointly with any other Person any Company Proprietary Asset that is material to the business of the Company and
with respect to which such other Person has any rights. Except as set forth in Part&nbsp;2.9(a)(v)&nbsp;of the Disclosure Schedule, there is no Company Contract pursuant to which any Person has
any right (whether or not currently exercisable) to use, license or otherwise exploit any Company Proprietary Asset. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2>&nbsp;The Company has taken reasonable measures and precautions to protect and maintain the confidentiality and value of
all Company Proprietary Assets (except Company Proprietary Assets whose value would be unimpaired by disclosure). Without limiting the generality of the foregoing, except as set forth in
Part&nbsp;2.9(b) of the Disclosure Schedule, the Company has secured agreements with each current or former employee, consultant and independent contractor of the Company who prior to the date
hereof was involved in, or who has contributed to, the creation or development of any Company Proprietary Asset identified or required to be on Part&nbsp;2.9(a)(i)&nbsp;or 2.9(a)(ii)&nbsp;of the
Disclosure Schedule (containing no exceptions to or exclusions from the scope of its coverage) securing ownership and assignment of any such contributions to the Company and which, in substance, are
the same in all material respects as the form of Confidential Information and Invention Assignment Agreement previously delivered by the Company to Parent. Other than with respect to ongoing royalty
and payment obligations under Material Contracts identified on Part&nbsp;2.10 of the Disclosure Schedule (with the exception of those identified under the heading "Confidential Disclosure
Agreements"), no current </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=3,SEQ=18,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=163754,FOLIO='11',FILE='DISK016:[01PAL5.01PAL2055]KI2055A.;7',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<A NAME="page_ki2055_1_12"> </A>

<P><FONT SIZE=2>
or former employee, officer, director, stockholder, consultant or independent contractor has any right, claim or interest in or with respect to any Company Proprietary Asset identified or required to
be on Part&nbsp;2.9(a)(i)&nbsp;or 2.9(a)(ii)&nbsp;of the Disclosure Schedule. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(c)</B></FONT><FONT SIZE=2>&nbsp;Except as set forth in Part&nbsp;2.9(c) of the Disclosure Schedule, (i)&nbsp;all patents, trademarks, service
marks and copyrights held by the Company are valid, enforceable and subsisting, (ii)&nbsp;none of the Company Proprietary Assets identified or required to be identified on
part&nbsp;2.9(a)(i)&nbsp;or Part&nbsp;2.9(a)(ii)&nbsp;of the Disclosure Schedule and to the knowledge of the Company and the Designated Shareholders none of the Company Proprietary Assets
identified or required to be identified on part&nbsp;2.9(a)(iii)&nbsp;of the Disclosure Schedule infringes, misappropriates or conflicts with any Proprietary Asset owned or used by any other
Person or has at any time infringed, misappropriated or made any unlawful or unauthorized use of any Proprietary Asset owned or used by any other Person; (iii)&nbsp;the Company has never received
any notice or other communication (in writing or otherwise) of any actual, alleged, possible or potential infringement, misappropriation or unlawful or unauthorized use of, any Proprietary Asset owned
or used by any other Person; and (iv)&nbsp;to the knowledge of the Company and the Designated Shareholders, no other Person is infringing, misappropriating or making any unlawful or unauthorized use
of, and no Proprietary Asset owned or used by any other Person infringes or conflicts with, any material Company Proprietary Asset. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(d)</B></FONT><FONT SIZE=2>&nbsp;Except as set forth in Section&nbsp;2.9(d) Company Proprietary Asset conforms with any enforceable specification,
documentation, performance standard, representation or statement made or provided with respect thereto by or on behalf of the Company; and there has not been any claim by any customer or other Person
alleging that any Company Proprietary Asset (including each version thereof that has ever been licensed or otherwise made available by the Company to any Person) does not conform with any
specification, documentation, performance standard, representation or statement made or provided by or on behalf of the Company, and, to the knowledge of the Company and Designated Shareholders, there
is no basis for any such claim. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(e)</B></FONT><FONT SIZE=2>&nbsp;Except as set forth in Part&nbsp;2.9(c) of the Disclosure Schedule, the Company Proprietary Assets constitute all
the Proprietary Assets necessary to enable the Company to conduct their business in the manner in which such business has been and is being conducted. Except under Material Contracts identified on
Part&nbsp;2.10 of the Disclosure Schedule (with the exception of those identified under the heading "Confidential Disclosure Agreements"), the Company has not licensed any of the material Company
Proprietary Assets to any Person on an exclusive basis. Except under Material Contracts identified on Part&nbsp;2.10 of the Disclosure Schedule, the Company has not entered into any covenant not to
compete or Contract limiting or purporting to limit the ability of the Company to exploit fully any material Company Proprietary Assets or to transact business in any market or geographical area or
with any Person. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;2.10&nbsp;&nbsp;Contracts</B></FONT><FONT SIZE=2>.&nbsp;&nbsp;</FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2>&nbsp;Part&nbsp;2.10 of the Disclosure Schedule lists or identifies: </FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(i)</B></FONT><FONT SIZE=2>&nbsp;each Company Contract relating to the employment of, or the performance of services by, any employee, consultant or
independent contractor which involves payments by the Company in excess of $100,000 annually or, with respect to employees, does not permit the Company to terminate the employment of such employee at
will and without the payment of severance; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(ii)</B></FONT><FONT SIZE=2>&nbsp;each Company Contract relating to the acquisition, transfer, use, development, sharing or license of any technology
or any Proprietary Asset; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(iii)</B></FONT><FONT SIZE=2>&nbsp;each Company Contract imposing any restriction on the Company's right or ability (A)&nbsp;to compete with any
other Person, (B)&nbsp;to acquire any product or other asset or any services from any other Person, to sell any product or other asset to or perform any services for any other Person or </FONT></P>

</UL>
<P ALIGN="CENTER"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=4,SEQ=19,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=638037,FOLIO='12',FILE='DISK016:[01PAL5.01PAL2055]KI2055A.;7',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<A NAME="page_ki2055_1_13"> </A>
<UL>

<P><FONT SIZE=2>
to transact business or deal in any other manner with any other Person, or (C)&nbsp;develop or distribute any technology; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(iv)</B></FONT><FONT SIZE=2>&nbsp;each Company Contract creating or involving any agency relationship, distribution arrangement or franchise
relationship involving payments to or from the Company in excess of $100,000 per year; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(v)</B></FONT><FONT SIZE=2>&nbsp;each Company Contract relating to the acquisition, issuance or transfer of any securities; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(vi)</B></FONT><FONT SIZE=2>&nbsp;each Company Contract relating to the voting and any other rights or obligations of a shareholder of the Company,
including, without limitation, any registration rights; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(vii)</B></FONT><FONT SIZE=2>&nbsp;each Company Contract relating to any merger, consolidation, reorganization or any similar transaction with
respect to the Company; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(viii)</B></FONT><FONT SIZE=2>&nbsp;each Company Contract relating to the creation of any Encumbrance with respect to any asset of the Company having
a value in excess of $100,000; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(ix)</B></FONT><FONT SIZE=2>&nbsp;each Company Contract involving or incorporating any guaranty, any pledge, any performance or completion bond, any
indemnity or any surety arrangement; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(x)</B></FONT><FONT SIZE=2>&nbsp;each Company Contract which provides for indemnification of any officer, director, employee or agent; </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(xi)</B></FONT><FONT SIZE=2>&nbsp;each Company Contract creating or relating to any partnership or joint venture or any sharing of revenues, profits,
losses, costs or liabilities; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(xii)</B></FONT><FONT SIZE=2>&nbsp;each Company Contract relating to the purchase or sale of any product or other asset by or to, or the performance
of any services by or for, any Related Party (as defined in Section&nbsp;2.18); </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(xiii)</B></FONT><FONT SIZE=2>&nbsp;each Company Contract constituting or relating to a Government Contract or Government Bid; </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(xiv)</B></FONT><FONT SIZE=2>&nbsp;any other Company Contract that was entered into outside the ordinary course of business or was inconsistent with
the Company's past practices; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(xv)</B></FONT><FONT SIZE=2>&nbsp;any other Company Contract that has a term of more than 60&nbsp;days and that may not be terminated by the
Company (without penalty) within 60&nbsp;days after the delivery of a termination notice by the Company; and </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(xvi)</B></FONT><FONT SIZE=2>&nbsp;any other Company Contract that contemplates or involves (A)&nbsp;the payment or delivery of cash or other
consideration in an amount or having a value in excess of $100,000 in the aggregate, or (B)&nbsp;the performance of services having a value in excess of $100,000 in the aggregate. </FONT></P>

</UL>

<P><FONT SIZE=2>(Contracts
in the respective categories described in clauses "(i)" through "(xvi)" above are referred to in this Agreement as "Material Contracts.") </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2>&nbsp;The Company has delivered to Parent or its counsel accurate and complete copies of all written Contracts identified
in Part&nbsp;2.10 of the Disclosure Schedule, including all amendments thereto. Part&nbsp;2.10 of the Disclosure Schedule provides an accurate description of the terms of each Company Contract
identified in Part&nbsp;2.10 of the Disclosure Schedule that is not in written form. Except as set forth on Part&nbsp;2.10 of the Disclosure Schedule, each Contract identified in Part&nbsp;2.10
of the Disclosure Schedule (other than Contracts, which by their terms have expired) is valid and in full force and effect, and, to the knowledge of the Company and the Designated Shareholders, is
enforceable in all material respects by the Company in accordance with its terms, subject to (i)&nbsp;laws of general application relating to bankruptcy, insolvency and the relief of debtors,
(ii)&nbsp;rules of law governing specific performance, injunctive relief and other equitable remedies, (iii)&nbsp;to the extent any indemnification or contribution </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=5,SEQ=20,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=192566,FOLIO='13',FILE='DISK016:[01PAL5.01PAL2055]KI2055B.;5',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<A NAME="page_ki2055_1_14"> </A>

<P><FONT SIZE=2>
provisions therein may be limited by applicable law; and (iv)&nbsp;such invalidity or unenforceability as could not reasonably be expected to have a Material Adverse Effect on the Company. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(c)</B></FONT><FONT SIZE=2>&nbsp;Except as set forth in Part&nbsp;2.10 of the Disclosure Schedule or as could not reasonably be expected to have a
Material Adverse Effect on the Company: </FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(i)</B></FONT><FONT SIZE=2>&nbsp;the Company has not violated or breached, or committed any default under, any Company Contract, and, to the
knowledge of the Company and the Designated Shareholders, no other Person has violated or breached, or committed any default under, any Company Contract; </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(ii)</B></FONT><FONT SIZE=2>&nbsp;to the knowledge of the Company and the Designated Shareholders, no event has occurred, and no circumstance or
condition exists, that (with or without notice or lapse of time) will, or could reasonably be expected to, (A)&nbsp;result in a violation or breach of any of the provisions of any Company Contract,
(B)&nbsp;give any Person the right to declare a default or exercise any remedy under any Company Contract, (C)&nbsp;give any Person the right to accelerate the maturity or performance of any
Company Contract, or (D)&nbsp;give any Person the right to cancel, terminate or modify any Company Contract; </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(iii)</B></FONT><FONT SIZE=2>&nbsp;since December&nbsp;31, 1997, the Company has not received any notice or other communication regarding any
actual or possible violation or breach of, or default under, any Company Contract; and </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(iv)</B></FONT><FONT SIZE=2>&nbsp;the Company has not waived any of its material rights under any Company Contract. </FONT></P>

</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(d)</B></FONT><FONT SIZE=2>&nbsp;No Person is renegotiating, or has a right pursuant to the terms of any Company Contract to renegotiate, any amount
paid or payable to the Company under any Material Contract or any other material term or provision of any Material Contract. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(e)</B></FONT><FONT SIZE=2>&nbsp;The Contracts identified in Part&nbsp;2.10 of the Disclosure Schedule collectively constitute all of the Contracts
necessary to enable the Company, in all material respects, to conduct its business in the manner in which its business is currently being conducted. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(f)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Part&nbsp;2.10 of the Disclosure Schedule identifies and provides a brief description of each proposed Contract
relating to a Company Proprietary Asset that could reasonably be expected to involve payments to or from the Company in excess of $100,000, and as to which any bid, offer, award, written proposal,
term sheet or similar document has been submitted or received by the Company since January&nbsp;1, 2001. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;2.11&nbsp;&nbsp;Liabilities</B></FONT><FONT SIZE=2>. The Company has no accrued, contingent or other liabilities of any nature, either matured or
unmatured, except for: (a)&nbsp;liabilities identified as such in the "liabilities" column of the Unaudited Interim Balance Sheet; (b)&nbsp;normal and recurring liabilities that have been incurred
by the Company since March&nbsp;31, 2001 in the ordinary course of business and consistent with the Company's past practices; (c)&nbsp;liabilities under the Company Contracts identified in
Part&nbsp;2.10 of the Disclosure Schedule that are expressly set forth in Part&nbsp;2.10 of the Disclosure Schedule and identifiable by reference to the text of such Company Contracts;
(d)&nbsp;the liabilities identified in Part&nbsp;2.11 of the Disclosure Schedule; and (e)&nbsp;liabilities that could not reasonably be expected to have a Material Adverse Effect on the Company. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;2.12&nbsp;&nbsp;Compliance with Legal Requirements.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;The Company is, and has at all times been, in compliance with
all applicable Legal Requirements, except where the failure to comply with such Legal Requirements has not had and will not have a Material Adverse Effect on the Company. Except as set forth in
Part&nbsp;2.12 of the Disclosure Schedule, since December&nbsp;31, 1997 the Company has not received
any notice or other communication from any Governmental Body regarding any actual or possible violation of, or failure to comply with, any Legal Requirement which violation or noncompliance could
reasonably be expected to have a Material Adverse Effect on the Company. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=6,SEQ=21,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=878542,FOLIO='14',FILE='DISK016:[01PAL5.01PAL2055]KI2055B.;5',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<A NAME="page_ki2055_1_15"> </A>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;2.13&nbsp;&nbsp;Governmental Authorizations.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Part&nbsp;2.13 of the Disclosure Schedule identifies each material
Governmental Authorization held by the Company, and the Company has delivered to Parent accurate and complete copies of all Governmental Authorizations identified in Part&nbsp;2.13 of the Disclosure
Schedule. The Governmental Authorizations identified in Part&nbsp;2.13 of the Disclosure Schedule are valid and in full force and effect, and collectively constitute all Governmental Authorizations
necessary to enable the Company to conduct its business in the manner in which its business is currently being conducted except where failure to hold such Government Authorization has not and could
not reasonably be expected to have a Material Adverse Effect on the Company. The Company is, and at all times has been, in substantial compliance with the terms and requirements of the respective
Governmental Authorizations identified or required to be identified in Part&nbsp;2.13 of the Disclosure Schedule. The Company has not received any notice or other communication from any Governmental
Body regarding (a)&nbsp;any actual or possible violation of or failure to comply with any such Governmental Authorization, or (b)&nbsp;any actual or possible revocation, withdrawal, suspension,
cancellation, termination or modification of any such Governmental Authorization. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;2.14&nbsp;&nbsp;Tax Matters</B></FONT><FONT SIZE=2>.&nbsp;&nbsp;</FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2>&nbsp;All Tax Returns required to be filed by or on behalf of the Company with any Governmental Body with respect to any
taxable period ending on or before the Closing Date (the "Company Returns") (i)&nbsp;have been or will be filed on or before the applicable due date (including any extensions of such due date) to
the extent required to be filed on or before the Closing Date, and (ii)&nbsp;have been, or will be when filed, prepared in all material respects in compliance with all applicable Legal Requirements
to the extent required to be filed on or before the Closing Date. All amounts shown to be due on or before the Closing Date on the Company Returns required to be filed on or before the Closing Date
have been or will be paid on or before the Closing Date. The Company has delivered to Parent copies of all Company Returns filed which have been requested by Parent. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2>&nbsp;The Company Financial Statements fully accrue all actual and contingent liabilities for Taxes with respect to all
periods through the dates thereof in accordance with generally accepted accounting principles. The Company has established a reserve in accordance with generally accepted accounting principles and
will continue to reserve on its books, consistent with its past practices, reserves adequate for the payment of all Taxes for the period from March&nbsp;31, 2001 through the Closing Date, and the
Company will disclose the dollar amount of such reserves to Parent on or prior to the Closing Date. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(c)</B></FONT><FONT SIZE=2>&nbsp;Except as set forth on Part&nbsp;2.14 of the Disclosure Schedule, no Company Return relating to income Taxes has
ever been examined or audited by any Governmental Body. Except as set forth in Part&nbsp;2.14 of
the Disclosure Schedule, there have been no examinations or audits of any Company Return. Except as set forth in Part&nbsp;2.14 of the Disclosure Schedule, no extension or waiver of the limitation
period applicable to any of the Company Returns has been granted (by the Company or any other Person), and no such extension or waiver has been requested from the Company. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(d)</B></FONT><FONT SIZE=2>&nbsp;Except as set forth in Part&nbsp;2.14 of the Disclosure Schedule, no claim or Proceeding is pending or to the
knowledge of the Company and the Designated Shareholders has been threatened against or with respect to the Company in respect of any Tax. There are no unsatisfied liabilities for Taxes (including
liabilities for interest, additions to tax and penalties thereon and related expenses) with respect to any notice of deficiency or similar document received by the Company with respect to any Tax
(other than liabilities for Taxes asserted under any such notice of deficiency or similar document which are being contested in good faith by the Company and with respect to which adequate reserves
for payment have been established). There are no liens for Taxes upon any of the assets of the Company except liens for current Taxes not yet due and payable. The Company has not entered into or
become bound by any agreement or consent pursuant to Section&nbsp;341(f) of the Code. Except as set forth on Part&nbsp;2.14 of the Disclosure Schedule, the Company has not been, and the Company
will not be, required to include any adjustment in taxable income for any tax period (or portion thereof) pursuant to Section&nbsp;481 or, to the knowledge of the Company and the Designated
Shareholders, 263A of the </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>

<!-- ZEQ.=7,SEQ=22,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=185890,FOLIO='15',FILE='DISK016:[01PAL5.01PAL2055]KI2055B.;5',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<A NAME="page_ki2055_1_16"> </A>

<P><FONT SIZE=2>
Code or any comparable provision under state or foreign Tax laws as a result of transactions or events occurring, or accounting methods employed, prior to the Closing. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(e)</B></FONT><FONT SIZE=2>&nbsp;Except as set forth on Part&nbsp;2.14 of the Disclosure Schedule, there is no agreement, plan, arrangement or
other Contract covering any employee or independent contractor or former employee or independent contractor of the Company that, considered individually or considered collectively with any other such
Contracts, will, or could reasonably be expected to, give rise directly or indirectly to the payment of any amount that would not be deductible pursuant to Section&nbsp;280G or Section&nbsp;162 of
the Code. The Company is not, and has never been, a party to or bound by any tax indemnity agreement, tax sharing agreement, tax allocation agreement, agreement to compensate any Person for any golden
parachute tax or similar Contract. The Company has not made a distribution of stock of a controlled corporation within the meaning of the Section&nbsp;355 of the Code. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;2.15&nbsp;&nbsp;Employee and Labor Matters; Benefit Plans</B></FONT><FONT SIZE=2>.&nbsp;&nbsp;</FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2>&nbsp;Part&nbsp;2.15(a) of the Disclosure Schedule identifies each salary, bonus, deferred compensation, incentive
compensation, stock purchase, stock option, severance pay, termination pay, hospitalization, medical, life or other insurance, supplemental unemployment benefits, profit-sharing, pension or retirement
plan, program or agreement (collectively, the "Plans") sponsored, maintained, contributed to or required to be contributed to by the Company for the benefit of any employee or director of the Company
("Employee"), except for Plans which would not require the Company to make payments or provide benefits having a value in excess of $10,000 in the aggregate. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2>&nbsp;Except as set forth in Part&nbsp;2.15(a) of the Disclosure Schedule, the Company does not maintain, sponsor or
contribute to, and, to the best of the knowledge of the Company and the Designated Shareholders, has not at any time in the past maintained, sponsored or contributed to, any employee pension benefit
plan (as defined in Section&nbsp;3(2) of the Employee Retirement Income Security Act of 1974, as amended ("ERISA"), whether or not excluded from coverage under specific Titles or Merger Subtitles of
ERISA) for the benefit of Employees or former Employees (a "Pension Plan"). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(c)</B></FONT><FONT SIZE=2>&nbsp;Except as set forth in Part&nbsp;2.15(c) of the Disclosure Schedule, the Company maintains, sponsors or
contributes only to those employee welfare benefit plans (as defined in Section&nbsp;3(1) of ERISA, whether or not excluded from coverage under specific Titles or Merger Subtitles of ERISA) for the
benefit of Employees or former Employees which are described in Part&nbsp;2.15(c) of the Disclosure Schedule (the "Welfare Plans"), none of which is a multiemployer plan (within the meaning of
Section&nbsp;3(37) of ERISA). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(d)</B></FONT><FONT SIZE=2>&nbsp;With respect to each Plan, the Company has delivered to Parent: </FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(i)</B></FONT><FONT SIZE=2>&nbsp;an accurate and complete copy of such Plan (including all amendments thereto); </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(ii)</B></FONT><FONT SIZE=2>&nbsp;an accurate and complete copy of the annual report, if required under ERISA, with respect to such Plan for the last
two years; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(iii)</B></FONT><FONT SIZE=2>&nbsp;an accurate and complete copy of the most recent summary plan description, together with each Summary of Material
Modifications updating the most recent summary plan description, if required under ERISA, with respect to such Plan, and all material employee communications relating to such Plan; </FONT></P>

</UL>
<P ALIGN="CENTER"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=8,SEQ=23,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=300855,FOLIO='16',FILE='DISK016:[01PAL5.01PAL2055]KI2055B.;5',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->

<P><FONT SIZE=2><A
NAME="page_kk2055_1_17"> </A> </FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(iv)</B></FONT><FONT SIZE=2>&nbsp;if such Plan is funded through a trust or any third party funding vehicle, an accurate and complete copy of the
trust or other funding agreement (including all amendments thereto) and accurate and complete copies the most recent financial statements thereof; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(v)</B></FONT><FONT SIZE=2>&nbsp;accurate and complete copies of all Contracts relating to such Plan, including service provider agreements,
insurance contracts, minimum premium contracts, stop-loss agreements, investment management agreements, subscription and participation agreements and recordkeeping agreements; and </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(vi)</B></FONT><FONT SIZE=2>&nbsp;an accurate and complete copy of the most recent determination letter received from the Internal Revenue Service
with respect to the standardized prototype 401(k) Plan which has been adopted by the Company (if such Plan is intended to be qualified under Section&nbsp;401(a) of the Code). </FONT></P>

</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(e)</B></FONT><FONT SIZE=2>&nbsp;The Company is not required to be, and, to the best of the knowledge of the Company and the Designated Shareholders,
has never been required to be, treated as a single employer with any other Person under Section&nbsp;4001(b)(1) of ERISA or Section&nbsp;414(b), (c), (m)&nbsp;or (o)&nbsp;of the Code. The
Company has never been a member of an "affiliated service group" within the meaning of Section&nbsp;414(m) of the Code. To the best of the knowledge of the Company and the Designated Shareholders,
the Company has never made a complete or partial withdrawal from a multiemployer plan, as such term is defined in Section&nbsp;3(37) of ERISA, resulting in "withdrawal liability," as such term is
defined in Section&nbsp;4201 of ERISA (without regard to subsequent reduction or waiver of such liability under either Section&nbsp;4207 or 4208 of ERISA). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(f)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;The Company does not have any plan or commitment to create any additional Welfare Plan or any Pension Plan, or to
modify or change any existing Welfare Plan or Pension Plan (other than to comply with applicable law) in a manner that would affect any Employee. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(g)</B></FONT><FONT SIZE=2>&nbsp;Except as set forth in Part&nbsp;2.15(g) of the Disclosure Schedule, no Welfare Plan provides death, medical or
health benefits (whether or not insured) with respect to any current or former Employee after any such Employee's termination of service (other than (i)&nbsp;benefit coverage mandated by applicable
law, including coverage provided pursuant to Section&nbsp;4980B of the Code, (ii)&nbsp;deferred compensation benefits accrued as liabilities on the Unaudited Interim Balance Sheet, and
(iii)&nbsp;benefits the full cost of which are borne by current or former Employees (or the Employees' beneficiaries)). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(h)</B></FONT><FONT SIZE=2>&nbsp;With respect to each of the Welfare Plans constituting a group health plan within the meaning of
Section&nbsp;4980B(g)(2) of the Code, the provisions of Section&nbsp;4980B of the Code ("COBRA") have been complied with in all material respects. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(i)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Each of the Plans has been operated and administered in all material respects in accordance with applicable Legal
Requirements, including but not limited to ERISA and the Code. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(j)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Each of the Plans intended to be qualified under Section&nbsp;401(a) of the Code has received a favorable
determination from the Internal Revenue Service, and neither the Company nor the Designated Shareholders is aware of any reason why any such determination letter should be revoked. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(k)</B></FONT><FONT SIZE=2>&nbsp;Except as set forth in Part&nbsp;2.15(k) of the Disclosure Schedule, neither the execution, delivery or
performance of this Agreement, nor the consummation of the Merger or any of the other transactions contemplated by this Agreement, will result in any payment (including any bonus, golden parachute or
severance payment) to any current or former Employee or director of the Company (whether or not under any Plan), or materially increase the benefits payable under any Plan, or result in any
acceleration of the time of payment or vesting of any such benefits, other than acceleration of vesting of the Company Options and immediate vesting upon termination of the Company's 401(k) Plan. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=24,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=378895,FOLIO='17',FILE='DISK016:[01PAL5.01PAL2055]KK2055A.;6',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<A NAME="page_kk2055_1_18"> </A>

<P><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>(l)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Part&nbsp;2.15(l) of the Disclosure Schedule contains a list of all salaried employees of the Company as of the
date of this Agreement, and correctly reflects, in all material respects, their salaries, any other compensation payable to them (including compensation payable pursuant to bonus, deferred
compensation or commission arrangements), their dates of employment and their positions. The Company is not a party to any collective bargaining contract or other Contract with a labor union involving
any of its Employees. All of the Company's employees are "at will" employees. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(m)</B></FONT><FONT SIZE=2>&nbsp;Part&nbsp;2.15(m) of the Disclosure Schedule identifies each Employee who is not fully available to perform work
because of disability or other leave and sets forth the basis of such leave and the anticipated date of return to full service. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(n)</B></FONT><FONT SIZE=2>&nbsp;The Company is in compliance in all material respects with all applicable Legal Requirements and Contracts relating
to employment, employment practices, wages, bonuses and terms and conditions of employment, including employee compensation matters. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(o)</B></FONT><FONT SIZE=2>&nbsp;Except as set forth in Part&nbsp;2.15(o) of the Disclosure Schedule, the Company has good labor relations, and
neither the Company nor the Designated Shareholders have any reason to believe that (i)&nbsp;the consummation of the Merger or any of the other transactions contemplated by this Agreement will have
a material adverse effect on the Company's labor relations, or (ii)&nbsp;any of the Company's employees intends to terminate his or her employment with the Company. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;2.16&nbsp;&nbsp;Environmental Matters.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;</FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2>&nbsp;Except as set forth on Part&nbsp;2.16(a) of the Disclosure Schedule, the Company (including with respect to all
property that is owned by, leased to, controlled by or used by the Company and all surface water, groundwater and soil associated with or adjacent to such property) is in compliance in all material
respects with all applicable Environmental Laws, which compliance includes the possession by the Company of all permits and other Governmental Authorizations required under applicable Environmental
Laws, and compliance with the terms and conditions thereof. Except as set forth on Part&nbsp;2.16(a) of the Disclosure Schedule, the Company has not received any notice or other communication (in
writing or otherwise), whether from a Governmental Body, citizens group, employee or otherwise, that alleges that the Company is not in compliance in all material respects with any Environmental Law,
and, to the knowledge of the Company and the Designated Shareholders, there are no circumstances that may prevent or interfere with the Company's compliance with any Environmental Law in the future.
To the knowledge of the Company and the Designated Shareholders, no current or prior owner of any property owned by, leased to, controlled by or used by the Company has received any notice or other
communication (in writing or otherwise), whether from a Government Body, citizens group, employee or otherwise, that alleges that such current or prior owner or the Company is not in compliance with
any Environmental Law. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2>&nbsp;Except as set forth in Part&nbsp;2.16(a) of the Disclosure Schedule, the Company has never received any notice or
other communication (in writing or otherwise) from any Governmental Body or other Person regarding any actual, alleged, possible or potential liability arising from or relating to the presence,
generation, manufacture, production, transportation, importation, use, treatment, refinement, processing, handling, storage, discharge, release, emission or disposal of any Materials of Environmental
Concern. Except as set forth in Part&nbsp;2.16(a) of the Disclosure Schedule, no Person has ever commenced or threatened to commence any contribution action or other Proceeding against the Company
in connection with any such actual, alleged, possible or potential liability; and no event has occurred, and no condition or circumstance exists, that may directly or indirectly give rise to, or
result in the Company becoming subject to, any such liability. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(c)</B></FONT><FONT SIZE=2>&nbsp;All material Governmental Authorizations currently held by the Company pursuant to Environmental Laws are identified
in Part&nbsp;2.16(c) of the Disclosure Schedule. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=25,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=1023332,FOLIO='18',FILE='DISK016:[01PAL5.01PAL2055]KK2055A.;6',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<A NAME="page_kk2055_1_19"> </A>

<P><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>(d)</B></FONT><FONT SIZE=2>&nbsp;The Company has never sent or transported, or arranged to send or transport, any Materials of Environmental Concern
to a site that, to the knowledge of the Company and the Designated Shareholders, pursuant to any applicable Environmental Law, (i)&nbsp;has been placed on the "National Priorities List" of hazardous
waste sites or any similar state list, (ii)&nbsp;is otherwise designated or identified as a potential site for remediation, cleanup, closure or other environmental remedial activity, or
(iii)&nbsp;is subject to a Legal Requirement to take "removal" or "remedial" action as detailed in any applicable Environmental Law or to make payment for the cost of cleaning up any site. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(e)</B></FONT><FONT SIZE=2>&nbsp;To the knowledge of the Company and the Designated Shareholders (after due inquiry), except as set forth in
Part&nbsp;2.16(e) of the Disclosure Schedule, the Company has never generated, manufactured, produced, transported, imported, used, treated, refined, processed, handled, stored, discharged, released
or disposed of any Materials of Environmental Concern (whether lawfully or unlawfully). To the knowledge of the Company and the Designated Shareholders (after due inquiry), except as set forth in
Part&nbsp;2.16(e) of the Disclosure Schedule, the Company has never permitted (knowingly or otherwise) any Materials of Environmental Concern to be generated, manufactured, produced, used, treated,
refined, processed, handled, stored, discharged, released or disposed of (whether lawfully or unlawfully): (i)&nbsp;on or beneath the surface of any real property that is, or that has at any time
been, owned by, leased to, controlled by or used by the Company; (ii)&nbsp;in or into any surface water, groundwater, soil or air associated with or adjacent to any such real property; or
(iii)&nbsp;in or into any well, pit, pond, lagoon, impoundment, ditch, landfill, building, structure, facility, improvement, installation, equipment, pipe, pipeline, vehicle or storage container
that is or was located on or beneath the surface of any such real property or that is or has at any time been owned by, leased to, controlled by or used by the Company in violation of any
Environmental Law. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(f)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Except as described on Part&nbsp;2.16(f) of the Disclosure Schedule, none of the property owned by, leased to,
controlled by or used by the Company contains any underground storage tanks, asbestos, equipment using PCBs, or underground injection wells. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;2.17&nbsp;&nbsp;Insurance.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Part&nbsp;2.17 of the Disclosure Schedule identifies all property and casualty
insurance policies maintained by, at the expense of or for the benefit of the Company relating to the business operations and assets of the Company and identifies any material claims made thereunder
since December&nbsp;31, 1997, and the Company has delivered to Parent accurate and complete copies of the insurance policies identified on Part&nbsp;2.17 of the Disclosure Schedule. Each of the
insurance policies identified in Part&nbsp;2.17 of the Disclosure Schedule is in full force and effect. Since December&nbsp;31, 1997, the Company has not received any notice or other communication
regarding any actual or possible (a)&nbsp;cancellation or invalidation of any such insurance policy, (b)&nbsp;refusal of any coverage or rejection of any claim under any such insurance policy, or
(c)&nbsp;material adjustment in the amount of the premiums payable with respect to any such insurance policy. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;2.18&nbsp;&nbsp;Related Party Transactions.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Except as set forth in Part&nbsp;2.18 of the Disclosure Schedule:
(a)&nbsp;no Related Party has, and no Related Party has at any time since December&nbsp;31, 1997 had, any direct or indirect interest in any material asset used in or otherwise relating to the
business of the Company; (b)&nbsp;no Related Party is, or has at any time since December&nbsp;31, 1997 been, indebted to the Company; (c)&nbsp;no Related Party has entered into, or has had since
December&nbsp;31, 1997 any direct or indirect financial interest in, any material Contract, transaction or business dealing involving the Company; (d)&nbsp;no Related Party is competing, or has at
any time, competed, directly or indirectly, with the
Company; and (e)&nbsp;no Related Party has any claim or right against the Company (other than rights under Company Options and rights to receive compensation for services performed as an employee of
the Company). (For purposes of the Section&nbsp;2.18 each of the following shall be deemed to be a "Related Party": (i)&nbsp;the Designated Shareholders; (ii)&nbsp;each individual who is, or who
has at any time been an officer of the Company; (iii)&nbsp;each member of the immediate family of each of the individuals referred to in clauses "(i)" and "(ii)" above; and (iv)&nbsp;any trust or
other Entity (other than the Company) in which any one of the individuals referred to in clauses "(i)," "(ii)" and "(iii)" above holds </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=3,SEQ=26,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=939663,FOLIO='19',FILE='DISK016:[01PAL5.01PAL2055]KK2055A.;6',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<A NAME="page_kk2055_1_20"> </A>

<P><FONT SIZE=2>
(or in which more than one of such individuals collectively hold), beneficially or otherwise, a material voting, proprietary or equity interest). </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;2.19&nbsp;&nbsp;Legal Proceedings; Orders</B></FONT><FONT SIZE=2>.&nbsp;&nbsp;</FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2>&nbsp;Except as set forth in Part&nbsp;2.19 of the Disclosure Schedule, there is no pending Legal Proceeding, and (to
the knowledge of the Company and the Designated Shareholders) no Person has overtly threatened to commence any Legal Proceeding: (i)&nbsp;that involves the Company or any of the assets owned or, to
the knowledge of the Company and the Designated Shareholders, assets used by the Company or any Person whose liability with respect to such Legal Proceeding the Company has or may have retained or
assumed, either contractually or by operation of law that could reasonably be expected to have a Material Adverse Effect on the Company; or (ii)&nbsp;that challenges, or that may have the effect of
preventing, delaying, making illegal or otherwise interfering with, the Merger or any of the other transactions contemplated by this Agreement. To the knowledge of the Company and the Designated
Shareholders, except as set forth in Part&nbsp;2.19 of the Disclosure Schedule, no event has occurred, and no claim, dispute or other condition or circumstance exists, that will, or that could
reasonably be expected to, give rise to or serve as a basis for the commencement of any Legal Proceeding that could reasonably be expected to have a Material Adverse Effect on the Company. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2>&nbsp;Except as set forth in Part&nbsp;2.19 of the Disclosure Schedule, since December&nbsp;31, 1997, no Legal
Proceeding has been commenced by or has been pending against the Company. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(c)</B></FONT><FONT SIZE=2>&nbsp;Except as set forth in Part&nbsp;2.19 of the Disclosure Schedule, there is no order, writ, injunction, judgment or
decree to which the Company, or any of the assets owned or used by the Company, is subject. The Designated Shareholders are not subject to any order, writ, injunction, judgment or decree that relates
to the Company's business or to any of the assets owned or used by the Company. No officer or, to the best of the knowledge of the Company and the Designated Shareholders, any other employee of the
Company is subject to any order, writ, injunction, judgment or decree that prohibits such officer or other employee from engaging in or continuing any conduct, activity or practice relating to the
Company's business. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;2.20&nbsp;&nbsp;Authority; Binding Nature of Agreement.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;</FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2>&nbsp;The Company has all requisite corporate power and authority to enter into and to consummate the transactions
contemplated hereby, subject to adoption of this Agreement by the Company's shareholders; and the execution and delivery of this Agreement and consummation by the Company of the transactions
contemplated by this Agreement have been duly authorized by all necessary action on the part of the Company and its board of directors, subject to the adoption of this Agreement by the Company's
shareholders and the filing of the Articles of Merger pursuant to the Alabama Business Corporation Act. Assuming due authorization, execution and delivery by Parent and Merger Sub of this Agreement
and assuming the adoption of this Agreement by the Company's shareholders, this Agreement will constitute the legal, valid and binding obligation of the Company, enforceable against the Company in
accordance with its terms, subject to (i)&nbsp;laws of general application relating to bankruptcy, insolvency and the relief of debtors and similar matters, and (ii)&nbsp;rules of law governing
specific performance, injunctive relief and other equitable remedies. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2>&nbsp;The Company's board of directors has (i)&nbsp;unanimously determined that the Merger is advisable and fair and in
the best interests of the Company and its stockholders; and (ii)&nbsp;unanimously recommended the approval and adoption of this Agreement to the holders of Company Common Stock and directed that
this Agreement and the Merger be submitted for consideration by the Company's shareholders in accordance with Section&nbsp;5.3. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(c)</B></FONT><FONT SIZE=2>&nbsp;No Alabama takeover statute or similar Legal Requirement of Alabama applies or purports to apply to the Merger, this
Agreement or any of the transactions contemplated hereby. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=4,SEQ=27,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=32129,FOLIO='20',FILE='DISK016:[01PAL5.01PAL2055]KK2055B.;9',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<A NAME="page_kk2055_1_21"> </A>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;2.21&nbsp;&nbsp;Non-Contravention; Consents.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Assuming (A)&nbsp;the proper filing of the Articles of
Merger pursuant to the Alabama Business Corporation Act, (B)&nbsp;the receipt of all Consents identified as being required on Part&nbsp;2.21 of the Disclosure Schedule, (C)&nbsp;proper Filings,
registrations, or declarations are made or obtained pursuant to the Securities Act, Exchange Act and securities laws of any foreign jurisdiction, and (D)&nbsp;the proper filings required to be made
under the HSR Act are made and applicable waiting periods have passed and compliance with any applicable antitrust laws of any foreign country, neither (1)&nbsp;the execution and delivery of this
Agreement or any of the other agreements referred to in this Agreement, nor (2)&nbsp;the consummation of the Merger or any of the other transactions contemplated by this Agreement, will directly or
indirectly (with or without notice or lapse of time): </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2>&nbsp;conflict with or result in a violation of (i)&nbsp;any of the provisions of the Company's articles of
incorporation or bylaws, or (ii)&nbsp;any resolution adopted by the Company's shareholders, the Company's board of directors or any committee of the Company's board of directors; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2>&nbsp;give any Governmental Body or other Person the right to challenge any of the transactions contemplated by this
Agreement; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(c)</B></FONT><FONT SIZE=2>&nbsp;conflict with or result in a violation of, or give any Governmental Body or other Person (other than shareholders of
the Company in connection with the exercise of their dissenters' rights) the right to exercise any remedy or obtain any relief under, any Legal Requirement or any order, writ, injunction, judgment or
decree to which the Company, or any of the assets owned or used by the Company, is subject except as could not reasonably be expected to have a Material Adverse Effect on the Company; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(d)</B></FONT><FONT SIZE=2>&nbsp;conflict with or result in a violation of any of the terms or requirements of, or give any Governmental Body the
right to revoke, withdraw, suspend, cancel, terminate or modify, any Governmental Authorization that is held by the Company or that otherwise relates to the Company's business or to any of the assets
owned or used by the Company except as could not reasonably be expected to have a Material Adverse Effect on the Company; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(e)</B></FONT><FONT SIZE=2>&nbsp;conflict with or result in a violation or breach of, or result in a default under, any provision of any Company
Contract that is or would constitute a Material Contract, or give any Person the right to (i)&nbsp;declare a default or exercise any remedy under any such Material Contract, (ii)&nbsp;accelerate
the maturity or performance of any such Material Contract, or (iii)&nbsp;cancel, terminate or modify any such Material Contract; or </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(f)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;result in the imposition or creation of any lien or other Encumbrance upon any asset owned or to the knowledge of
the Company and the Designated Shareholders, any asset used by the Company (except for liens that will not, in any case or in the aggregate, materially detract from the value of the assets subject
thereto or materially impair the operations of the Company). </FONT></P>

<P><FONT SIZE=2>Except
as set forth in Part&nbsp;2.21 of the Disclosure Schedule, the Company is not and will not be required to make any filing with or give any notice to, or to obtain any Consent from, any Person
in connection with (x)&nbsp;the execution and delivery of this Agreement or any of the other agreements referred to in this Agreement or (y)&nbsp;the consummation of the Merger or any of the other
transactions contemplated by this Agreement except for the filing of the Articles of Merger pursuant to the Alabama Business Corporation Act, and such filings as may be required under the HSR Act and
the antitrust laws of any foreign country. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;2.22&nbsp;&nbsp;Vote Required.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;The affirmative vote of the holders of two-thirds of the Company Common
Stock, voting as a single class, outstanding on the record date for the Company's stockholders' meeting (or the written consent in lieu thereof) is the only vote of the holders of any class or series
of the Company's capital stock necessary to adopt this Agreement and approve the Merger and the other transactions contemplated by this Agreement. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=5,SEQ=28,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=394522,FOLIO='21',FILE='DISK016:[01PAL5.01PAL2055]KK2055B.;9',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<A NAME="page_kk2055_1_22"> </A>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;2.23&nbsp;&nbsp;Full Disclosure</B></FONT><FONT SIZE=2>. This Agreement (including the Disclosure Schedule) does not, and the Closing Certificate will
not, (i)&nbsp;contain any representation, warranty or information that is false or misleading with respect to any material fact, or (ii)&nbsp;omit to state any material fact necessary in order to
make the representations, warranties and information contained and to be contained herein and therein (in the light of the circumstances under which such representations, warranties and information
were or will be made or provided) not false or misleading. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;2.24&nbsp;&nbsp;Financial Advisor</B></FONT><FONT SIZE=2>. Except for Robertson Stephens,&nbsp;Inc., no broker, finder or investment banker is entitled
to any brokerage, finder's or other fee or commission in connection with the Merger or any of the other transactions contemplated by this Agreement based upon arrangements made by or on behalf of the
Company. The total of all fees, commissions and other amounts that have been paid by the Company to Robertson Stephens,&nbsp;Inc. and all fees, commissions and other amounts that may become payable
to Robertson Stephens,&nbsp;Inc. by the Company if the Merger is consummated will not exceed the amounts to be paid pursuant to the agreements listed on Part&nbsp;2.24 of the Disclosure Schedule.
The Company has furnished to Parent accurate and complete copies of all agreements under which any such fees, commissions or other amounts have been paid to may become payable and all indemnification
and other agreements related to the engagement of Robertson Stephens,&nbsp;Inc. </FONT></P>


<P><FONT SIZE=2><B>SECTION 3. REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Parent and Merger Sub jointly and severally represent and warrant to the Company and the Signing Shareholders as follows: </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;3.1&nbsp;&nbsp;Due Organization.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Parent is a corporation duly organized, validly existing and in good standing
under the laws of the State of Delaware and has full power (corporate and other) and authority to conduct its business in the manner in which its business is currently being conducted and to own and
use its assets in the manner in which its assets are currently owned and used and to perform its obligations under any Contract by which it is bound. Merger Sub is a corporation duly organized,
validly existing and in good standing under the laws of the State of Alabama and has full power (corporate and other) and authority to conduct its business in the manner in which its business is
currently being conducted and to own and use its assets in the manner in which its assets are currently owned and used and to perform its obligations under any Contract by which it is bound. Each of
Parent and Merger Sub is duly qualified to do business as a foreign corporation, and is in good standing, under the laws of all jurisdictions where the nature of its business requires such
qualification and where the failure to be so qualified would have a Material Adverse Effect on Parent or Merger Sub. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;3.2&nbsp;&nbsp;SEC Filings; Financial Statements</B></FONT><FONT SIZE=2>.&nbsp;&nbsp;</FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2>&nbsp;Parent has delivered to the Company accurate and complete copies (excluding copies of exhibits) of each report,
registration statement (on a form other than Form&nbsp;S-3 or S-8) and definitive proxy statement filed by Parent with the SEC between January&nbsp;1, 2000 and the date of
this Agreement (the "Parent SEC Documents"). Since January&nbsp;1, 2000, all reports required to have been filed by the Parent with the SEC have been so filed. As of the time it was filed with the
SEC (or, if amended or superseded by a filing prior to the date of this Agreement, then on the date of such filing) each of the Parent SEC Documents complied in all material respects with the
applicable requirements of the Securities Act or the Exchange Act (as the case may be). The Parent SEC Documents (as of the time they were filed, or if amended or superseded by a filing prior to the
date of this Agreement, then on the date of such filing) did not contain, this Agreement does not contain, and the certificate to be delivered pursuant to Section&nbsp;7.5(b) herein will not
contain, any untrue statement of a material fact and the Parent SEC Documents (as of the time they were filed, or if amended or superseded by a filing prior to the date of this Agreement, then on the
date of such filing) did not omit, this Agreement does not omit and the certificate to be delivered pursuant to Section&nbsp;7.5(b) herein will not omit to state a material fact required to be
stated therein or necessary in order to make the statements therein, in the </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=6,SEQ=29,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=947351,FOLIO='22',FILE='DISK016:[01PAL5.01PAL2055]KK2055B.;9',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<A NAME="page_kk2055_1_23"> </A>

<P><FONT SIZE=2>
light of the circumstances under which they were, are or will be made (as the case may be), not misleading. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2>&nbsp;The consolidated financial statements contained in the Parent SEC Documents: (i)&nbsp;complied as to form in all
material respects with the published rules and regulations of the SEC applicable thereto; (ii)&nbsp;were prepared in accordance with generally accepted accounting principles applied on a consistent
basis throughout the periods covered, except as may be indicated in the notes to such financial statements and (in the case of unaudited statements) as permitted by Form&nbsp;10-Q of the
SEC, and except that unaudited financial statements may not contain footnotes and are subject to year-end audit adjustments; and (iii)&nbsp;fairly present the consolidated financial
position of Parent and its subsidiaries as of the respective dates thereof and the consolidated results of operations of Parent and its subsidiaries for the periods covered thereby. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;3.3&nbsp;&nbsp;Authority; Binding Nature of Agreement.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Parent and Merger Sub have all requisite corporate power
and authority to enter into and to consummate the transactions contemplated by this Agreement; and the execution, delivery and performance by Parent and Merger Sub of this Agreement (including the
contemplated issuance of Parent Common Stock in the Merger in accordance with this Agreement) have been duly authorized by all necessary action on the part of Parent and Merger Sub and their
respective boards of directors subject to the filing of the Articles of Merger pursuant to the Alabama Business Corporation Act. No vote of Parent's stockholders is needed to approve the Merger.
Assuming due authorization, execution and delivery by the Company and adoption of this Agreement by the Company's shareholders, this Agreement will constitute the legal, valid and binding obligation
of Parent and Merger Sub, enforceable against them in accordance with its terms, subject to (i)&nbsp;laws of general application relating to bankruptcy, insolvency and the relief of debtors and
similar matters, and (ii)&nbsp;rules of law governing specific performance, injunctive relief and other equitable remedies. </FONT></P>


<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;3.4&nbsp;&nbsp;Valid Issuance.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;The Parent Common Stock to be issued in the Merger will, when issued in accordance
with the provisions of this Agreement, be validly issued, fully paid and nonassessable. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;3.5&nbsp;&nbsp;Non-Contravention; Consents.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Assuming (A)&nbsp;the proper filing of the Articles of
Merger pursuant to the Alabama Business Corporation Act, (B)&nbsp;proper filings, registrations, or declarations are made or obtained pursuant to the Securities Act, Exchange Act, any state
securities laws or securities laws of foreign jurisdictions; (C)&nbsp;the proper filings required to be made under the HSR Act are made and applicable waiting periods have passed and compliance with
any applicable antitrust laws of any foreign country; and (D)&nbsp;the truth and accuracy of the representations of the Company's shareholders set forth in the Shareholders' Certificates, except as
could not reasonably be expected to have a Material Adverse Effect on parent neither (a)&nbsp;the execution, delivery or performance of this Agreement or any of the other agreements referred to in
this Agreement, nor (b)&nbsp;the consummation of the Merger or any of the other transactions contemplated by this Agreement, will directly or indirectly (with or without notice or lapse of time)
(1)&nbsp;conflict with or result in a violation of (i)&nbsp;any of the provisions of the certificate or articles of incorporation (as applicable) or bylaws of Parent or Merger Sub, (ii)&nbsp;any
resolution adopted by the stockholders, the board of directors or any committee of the board of directors of Parent or Merger Sub, (iii)&nbsp;any provision of any Contract filed as an exhibit to any
of the Parent SEC Documents or (iv)&nbsp;any Legal Requirement applicable to Parent or Merger Sub; (2)&nbsp;give any Governmental Body or other Person the right to challenge the Merger or any of
the other transactions contemplated by this Agreement or to exercise any remedy or obtain any relief under any order, writ, injunction, judgment, or decree to which Parent or Merger Sub or any of the
assets owned, or to the knowledge of Parent and Merger Sub, asset used by Parent or Merger Sub; (3)&nbsp;conflict with result in the violation of the terms or requirements of, or give any
Governmental Body the right to revoke, withdraw, suspend, cancel, terminate or modify any Governmental Authorization that is held by Parent or Merger Sub or that otherwise relates to the business of
Parent or Merger Sub or any of the assets owned, or to the knowledge of Parent and Merger Sub, assets used by Parent or Merger Sub; or (4)&nbsp;conflict with or result in a material violation or
breach of, or result in a material default under, any </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=7,SEQ=30,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=238379,FOLIO='23',FILE='DISK016:[01PAL5.01PAL2055]KK2055B.;9',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<A NAME="page_kk2055_1_24"> </A>

<P><FONT SIZE=2>
provision of any material Contract to which Parent or Merger Sub is a party or give any person the right to (i)&nbsp;declare a default or exercise any remedy under any such material Contract,
(ii)&nbsp;accelerate the maturity or performance of any such material Contract, or (iii)&nbsp;cancel, terminate or materially modify any term of such material contract. Neither Parent nor Merger
Sub will be required to make any filing with or give any notice to, or to obtain any Consent from, any Person in connection with (x)&nbsp;the execution, delivery or performance of this Agreement or
any of the other agreements referred to in this Agreement, or (y)&nbsp;the consummation of the Merger or any of the other transactions contemplated by this Agreement, except for (A)&nbsp;the
filing of the articles of merger with the Secretary of State of the State of Alabama, (B)&nbsp;the filing of a Notification of Listing of Additional Shares with the Nasdaq National Market,
(C)&nbsp;the filings required under the HSR Act, and (D)&nbsp;such filings, registrations, declarations and reports as required pursuant to the Securities Act, Exchange Act, state securities laws
or securities laws of foreign jurisdictions. </FONT></P>


<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;3.6&nbsp;&nbsp;Capitalization</B></FONT><FONT SIZE=2>&nbsp;&nbsp;</FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2>&nbsp;The authorized capital stock of Parent consists of 300,000,000 of Parent Common Stock, of which 51,485,207 shares
were issued and outstanding as of March&nbsp;31, 2001 and 10,000,000 shares of preferred stock, of which no shares were issued and outstanding as of March&nbsp;31, 2001. All of the outstanding
shares of Parent Common Stock have been duly authorized and validly issued and are fully paid and nonassesable. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2>&nbsp;As of March&nbsp;31, 2001, an aggregate of 11,432,000 shares of Parent Common Stock were subject to outstanding
options to purchase shares of Parent Common Stock pursuant to the Company's 2000 Non-Officer Equity Incentive Plan, as amended, 2000 Equity Incentive Plan and 1994 Non-Employee
Director Stock Option Plan, as amended and options assumed in connection with the acquisition of Bradford Particle Design, plc. Except (i)&nbsp;as set forth above, (ii)&nbsp;as set forth in the
Parent SEC Documents, (iii)&nbsp;outstanding warrants to purchase 56,000 shares of Parent Common Stock, (iv)&nbsp;conversion rights of Parent's outstanding 6<SUP>3</SUP>/<SMALL>4</SMALL>% convertible
subordinated debentures due October&nbsp;2007, (v)&nbsp;conversion rights of Parent's outstanding 5% convertible subordinated notes due February&nbsp;2005, and (vi)&nbsp;conversion rights of
Parent's outstanding 3<SUP>1</SUP>/<SMALL>2</SMALL>% convertible subordinated notes due October&nbsp;2005, as of March&nbsp;31, 2001, there were not outstanding subscriptions, options or warrants granted by
Parent to acquire any shares of Parent Common Stock or outstanding securities, interests or obligations of Parent convertible into or exchangeable for any shares of Parent Common Stock. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(c)</B></FONT><FONT SIZE=2>&nbsp;Except as set forth in (A)&nbsp;the Parent SEC Documents; (B)&nbsp;that certain Restated Investor Rights
Agreement dated April&nbsp;29, 1993, as amended; (C)&nbsp;that certain Stock Purchase Agreement dated January&nbsp;18, 1995; (D)&nbsp;that certain Stock Purchase Agreement dated
March&nbsp;1, 1996; (E)&nbsp;those certain Stock Purchase Agreements dated January&nbsp;28, 1997; (F)&nbsp;that certain Stock Purchase Agreement dated December&nbsp;8, 1998; (G)&nbsp;that
certain Resale Registration Rights Agreement dated October&nbsp;13, 1999; (H)&nbsp;that certain Registration Rights Agreement dated January&nbsp;25, 2000; (I)&nbsp;that certain Resale
Registration Rights Agreement dated February&nbsp;8, 2000; (J)&nbsp;that certain Resale Registration Rights Agreement dated October&nbsp;17, 2000; and (J)&nbsp;that certain Offer Document
dated December&nbsp;21, 2000 (i)&nbsp;none of the outstanding shares of Parent Common Stock is entitled to or subject to any premptive right, right of first offer or similar right created by
Parent or imposed by applicable law with respect to Parent Common Stock; and (ii)&nbsp;there is no contract to which Parent is party relating to the registration of any shares of Parent Common
Stock. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(d)</B></FONT><FONT SIZE=2>&nbsp;The authorized capital stock of Merger Sub consists of 1,000 shares of common stock, all of which are issued and
outstanding and held by Parent. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;3.7&nbsp;&nbsp;Absence of Changes</B></FONT><FONT SIZE=2>. Since March&nbsp;31, 2001, no event has occurred that will or could reasonably be expected to
have a Material Adverse Effect on Parent. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=8,SEQ=31,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=743870,FOLIO='24',FILE='DISK016:[01PAL5.01PAL2055]KK2055B.;9',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<A NAME="page_kk2055_1_25"> </A>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;3.8&nbsp;&nbsp;Liabilities</B></FONT><FONT SIZE=2>. Except for the transactions contemplated herein or as reflected in the Parent SEC Documents, Parent
has no accrued, contingent or other liabilities of any nature, either mature or unmatured, which could reasonably be expected to have a Material Adverse Effect on Parent. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;3.9&nbsp;&nbsp;Legal Proceedings</B></FONT><FONT SIZE=2>. Except as disclosed in the Parent SEC Documents, there is no pending Legal Proceeding and (to
the knowledge of Parent) no Person has overtly threatened to commence any Legal Proceeding (i)&nbsp;that involves Parent or any of the assets owned or, to the knowledge of Parent, assets used by
Parent and that, if adversely determined, would reasonably be expected to have a Material Adverse Effect on Parent; or (ii)&nbsp;challenges, or that may have the effect of preventing, delaying,
making illegal or otherwise interfering with, the Merger or any of the other transactions contemplated by this Agreement. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;3.10&nbsp;&nbsp;Compliance with Legal Requirements</B></FONT><FONT SIZE=2>. Parent is in compliance with all applicable Legal Requirements except where
the failure to so comply would not reasonably be expected to have a Material Adverse Effect on Parent. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;3.11&nbsp;&nbsp;Proprietary Assets</B></FONT><FONT SIZE=2>. Except as disclosed in the SEC Documents or Part&nbsp;3.11 of Parent's Disclosure Schedule,
Parent owns all Proprietary Assets claimed to be owned by Parent that are material to the business of Parent, free and clear of all Encumbrances, except for any lien for current taxes not yet due and
payable, and minor liens that have arisen in the ordinary course of business and that do not (individually or in the aggregate) materially detract from the value of the assets subject thereto or
materially impair the operations of Parent. To its knowledge, Parent has a valid right to use, license and otherwise exploit all Proprietary Assets licensed or otherwise made available to Parent that
are material to Parent. Except as disclosed in the Parent SEC Documents, Parent has not developed jointly with any other Person any Proprietary Asset that is material to the business of the Parent
with respect to which such other Person has any rights. Parent has taken commercially reasonable measures and precautions to protect and maintain the confidentiality of all material Parent Proprietary
Assets (except Parent Proprietary Assets whose value would be unimpaired by disclosure). </FONT></P>

<P><FONT SIZE=2><B>SECTION 4. CERTAIN COVENANTS OF THE COMPANY AND THE SIGNING SHAREHOLDERS  </B></FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;4.1&nbsp;&nbsp;Access and Investigation.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;During the period from the date of this Agreement through the Effective
Time (the "Pre-Closing Period"), the Company shall, and shall cause its Representatives to: (a)&nbsp;provide Parent and Parent's Representatives with reasonable access to the Company's
Representatives, personnel and assets and to all existing books, records, Tax Returns, work papers and other documents and information relating to the Company; and (b)&nbsp;provide Parent and
Parent's Representatives with copies of such existing books, records, Tax Returns, work papers and other documents and information relating to the Company, and with such additional financial,
operating and other data and information regarding the Company, as Parent may reasonably request. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;4.2&nbsp;&nbsp;Operation of the Company's Business</B></FONT><FONT SIZE=2>. During the Pre-Closing Period: </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2>&nbsp;the Company shall conduct its business and operations in the ordinary course and in substantially the same manner as
such business and operations have been conducted prior to the date of this Agreement; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2>&nbsp;the Company shall use reasonable efforts to preserve intact its current business organization, keep available the
services of its current officers and employees and maintain its relationship with all suppliers, customers, landlords, creditors, employees and other Persons having business relationships with the
Company; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(c)</B></FONT><FONT SIZE=2>&nbsp;the Company shall keep in full force all insurance policies identified in Part&nbsp;2.17 of the Disclosure
Schedule; </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=9,SEQ=32,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=336997,FOLIO='25',FILE='DISK016:[01PAL5.01PAL2055]KK2055B.;9',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->

<P><FONT SIZE=2><A
NAME="page_km2055_1_26"> </A>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>(d)</B></FONT><FONT SIZE=2>&nbsp;the Company shall cause its officers to report regularly (but in no event less frequently than weekly) to Parent
concerning the status of the Company's business; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(e)</B></FONT><FONT SIZE=2>&nbsp;the Company shall not declare, accrue, set aside or pay any dividend or make any other distribution in respect of
any shares of capital stock, and shall not repurchase, redeem or otherwise reacquire any shares of capital stock or other securities; </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(f)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;the Company shall not sell, issue or authorize the issuance of (i)&nbsp;any capital stock or other security,
(ii)&nbsp;any option or right to acquire any capital stock or other security, or (iii)&nbsp;any instrument convertible into or exchangeable for any capital stock or other security other than the
issuance, delivery and or sale of Company Common Stock pursuant to the exercise of Company Options; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(g)</B></FONT><FONT SIZE=2>&nbsp;the Company shall not amend or waive any of its rights under, or permit the acceleration of vesting under (except to
the extent acceleration of vesting occurs as a result of transactions contemplated herein and waivers and amendments contemplated by this Agreement) (i)&nbsp;any provision of its 1996 Nonqualified
Stock Option Plan, (ii)&nbsp;any provision of any agreement evidencing any outstanding Company Option, or (iii)&nbsp;any provision of any restricted stock purchase agreement; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(h)</B></FONT><FONT SIZE=2>&nbsp;neither the Company nor Signing Shareholders shall amend or permit the adoption of any amendment to the Company's
articles of incorporation or bylaws, or effect or permit the Company to become a party to any Acquisition Transaction, recapitalization, reclassification of shares, stock split, reverse stock split or
similar transaction; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(i)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;the Company shall not form any subsidiary or acquire any equity interest or other interest in any other Entity; </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(j)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;the Company shall not make any capital expenditure, except for capital expenditures that, when added to all other
capital expenditures made on behalf of the Company during the Pre-Closing Period, do not exceed $100,000 and except for capital expenditures in connection with the construction of the
Company's building located at Discovery Drive, Huntsville, Alabama which shall not exceed the amounts set forth on Part&nbsp;4.2(j) of the Disclosure Schedule or be made other than in connection
with the expenditures specifically described on Part&nbsp;4.2(j) of the Disclosure Schedule; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(k)</B></FONT><FONT SIZE=2>&nbsp;the Company shall not (i)&nbsp;enter into, or permit any of the assets owned or used by it to become bound by, any
Contract that is or would constitute a Material Contract relating to any Company Proprietary Asset or involving payments or obligations in excess of $100,000, or (ii)&nbsp;amend or prematurely
terminate, or waive any material right or remedy under, any such Contract; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(l)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;the Company shall not (i)&nbsp;acquire, lease or license any real property, Proprietary Asset or other right or
asset ("Other Asset"), which Other Asset has a value in excess of $100,000, from any other Person, (ii)&nbsp;sell or otherwise dispose of, or lease or license, any real property, Proprietary Asset
or Other Asset, which Other Asset has a value in excess of $100,000, to any other Person, or (iii)&nbsp;waive or relinquish any right, except for assets acquired, leased, licensed or disposed of by
the Company pursuant to Contracts that are not related to real property or Proprietary Assets, or involve payments or obligations less than $100,000; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(m)</B></FONT><FONT SIZE=2>&nbsp;the Company shall not (i)&nbsp;lend money to any Person (except that the Company may make routine travel advances
to employees in the ordinary course of business), or (ii)&nbsp;incur or guarantee any indebtedness for borrowed money other than (A)&nbsp;in connection with the financing of trade payables in the
ordinary course of business consistent with past practices; or (B)&nbsp;pursuant to existing credit facilities in the ordinary course of business; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(n)</B></FONT><FONT SIZE=2>&nbsp;the Company shall not (i)&nbsp;establish, adopt or amend any Employee Benefit Plan; (ii)&nbsp;pay any bonus or
make any profit-sharing payment, cash incentive payment or similar payment to, or increase the amount of the wages, salary, commissions, fringe benefits or other compensation or remuneration payable
to, any of its directors, officers or employees other than bonuses and raises paid in the </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>26</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=33,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=991305,FOLIO='26',FILE='DISK016:[01PAL5.01PAL2055]KM2055A.;6',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<A NAME="page_km2055_1_27"> </A>

<P><FONT SIZE=2>
ordinary course of business, in accordance with past practice and which will not exceed $5,000 individually or $100,000 in the aggregate; or (iii)&nbsp;hire any new employee whose aggregate annual
compensation is expected to exceed $40,000; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(o)</B></FONT><FONT SIZE=2>&nbsp;the Company shall not change any of its methods of accounting or accounting practices in any material respect; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(p)</B></FONT><FONT SIZE=2>&nbsp;the Company shall not make any Tax election (except to the extent the filing of Tax Return constitutes an election); </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(q)</B></FONT><FONT SIZE=2>&nbsp;the Company shall not commence or settle any material Legal Proceeding; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(r)</B></FONT><FONT SIZE=2>&nbsp;the Company shall not agree or commit to take any of the actions described in clauses "(e)" through "(q)" above. </FONT></P>


<P><FONT SIZE=2>Notwithstanding
the foregoing, the Company may take any action described in clauses "(a)" through "(r)" above if (A)&nbsp;provided on Part&nbsp;4.2 of the Disclosure Schedule, (B)&nbsp;Parent
gives its prior written consent to the taking of such action by the Company, which consent will not be unreasonably withheld (it being understood that Parent's withholding of consent to any action
will not be deemed unreasonable if Parent determines in good faith that the taking of such action would not be in the best interests of Parent or would not be in the best interests of the Company), or
(C)&nbsp;contemplated or permitted by this Agreement. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;4.3&nbsp;&nbsp;Notification; Updates to Disclosure Schedule.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;</FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2>&nbsp;During the Pre-Closing Period, the Company shall use reasonable commercial efforts to promptly notify
Parent in writing of: </FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(i)</B></FONT><FONT SIZE=2>&nbsp;the discovery by the Company of any event, condition, fact or circumstance that occurred or existed on or prior to
the date of this Agreement and that caused or constitutes an inaccuracy in or breach of any representation or warranty made by the Company or the Designated Shareholders in this Agreement; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(ii)</B></FONT><FONT SIZE=2>&nbsp;any event, condition, fact or circumstance that occurs, arises or exists after the date of this Agreement and that
the Company, in good faith believes, would cause or constitute a material inaccuracy in or material breach of any representation or warranty made by the Company or the Designated Shareholders in this
Agreement if (A)&nbsp;such representation or warranty had been made as of the time of the occurrence, existence or discovery of such event, condition, fact or circumstance, or (B)&nbsp;such event,
condition, fact or circumstance had occurred, arisen or existed on or prior to the date of this Agreement; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(iii)</B></FONT><FONT SIZE=2>&nbsp;any breach of any covenant or obligation of the Company or the Signing Shareholders; and </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(iv)</B></FONT><FONT SIZE=2>&nbsp;any event, condition, fact or circumstance that would make the timely satisfaction of any of the conditions set
forth in Section&nbsp;6 or Section&nbsp;7 impossible or unlikely. </FONT></P>

</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2>&nbsp;If any event, condition, fact or circumstance that is required to be disclosed pursuant to Section&nbsp;4.3(a)
requires any change in the Disclosure Schedule, or if any such event, condition, fact or circumstance would require such a change assuming the Disclosure Schedule were dated as of the date
of the occurrence, existence or discovery of such event, condition, fact or circumstance, then the Company shall promptly deliver to Parent an update to the Disclosure Schedule specifying such change.
No such update shall be deemed to supplement or amend the Disclosure Schedule for the purpose of (i)&nbsp;determining the accuracy of any of the representations and warranties made by the Company or
the Designated Shareholders in this Agreement, or (ii)&nbsp;determining whether any of the conditions set forth in Section&nbsp;6 has been satisfied. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>27</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=34,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=925733,FOLIO='27',FILE='DISK016:[01PAL5.01PAL2055]KM2055A.;6',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<A NAME="page_km2055_1_28"> </A>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;4.4&nbsp;&nbsp;No Negotiation.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;During the Pre-Closing Period, neither the Company, its
Representatives, nor the Signing Shareholders shall, directly or indirectly: </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2>&nbsp;solicit or encourage the initiation of any inquiry, proposal or offer from any Person (other than Parent) relating
to a possible Acquisition Transaction; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2>&nbsp;participate in any discussions or negotiations or enter into any agreement with, or provide any
non-public information to, any Person (other than Parent) relating to or in connection with a possible Acquisition Transaction; or </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(c)</B></FONT><FONT SIZE=2>&nbsp;consider, entertain or accept any proposal or offer from any Person (other than Parent) relating to a possible
Acquisition Transaction. </FONT></P>

<P><FONT SIZE=2>The
Company shall promptly notify Parent in writing of any material inquiry, proposal or offer relating to a possible Acquisition Transaction that is received by the Company or the Signing
Shareholders during the Pre-Closing Period. </FONT></P>

<P><FONT SIZE=2><B>SECTION 5. ADDITIONAL COVENANTS OF THE PARTIES  </B></FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;5.1&nbsp;&nbsp;Filings and Consents.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;As promptly as practicable after the execution of this Agreement, each party
to this Agreement (a)&nbsp;shall make all filings (if any) and give all notices (if any) required to be made and given by such party in connection with the Merger and the other transactions
contemplated by this Agreement, and (b)&nbsp;shall use all commercially reasonable efforts to obtain all Consents (if any) required to be obtained (pursuant to any applicable Legal Requirement or
Contract, or otherwise) by such party in connection with the Merger and the other transactions contemplated by this Agreement. Without
limiting the generality of the foregoing, the Company and Parent shall, promptly after the date of this Agreement, prepare and file the notifications required under the HSR Act in connection with the
Merger. The Company and Parent shall respond as promptly as practicable to (i)&nbsp;any inquiries or requests received from the Federal Trade Commission or the Department of Justice for additional
information or documentation and (ii)&nbsp;any inquiries or requests received from any state attorney general or other Governmental Body in connection with antitrust or related matters. Each of the
Company and Parent shall (1)&nbsp;give the other party prompt notice of the commencement of any Legal Proceeding by or before any Governmental Body with respect to the Merger or any of the other
transactions contemplated by this Agreement, (2)&nbsp;keep the other party informed as to the status of any such Legal Proceeding, and (3)&nbsp;promptly inform the other party of any communication
to or from the Federal Trade Commission, the Department of Justice or any other Governmental Body regarding the Merger. The Company and Parent will consult and cooperate with one another, and will
consider in good faith the views of one another, in connection with any analysis, appearance, presentation, memorandum, brief, argument, opinion or proposal made or submitted in connection with any
Legal Proceeding under or relating to the HSR Act or any other federal or state antitrust or fair trade law. In addition, except as may be prohibited by any Governmental Body or by any Legal
Requirement, in connection with any Legal Proceeding under or relating to the HSR Act or any other federal or state antitrust or fair trade law or any other similar Legal Proceeding, each of the
Company and Parent agrees to permit authorized Representatives of the other party to be present at each meeting or conference relating to any such Legal Proceeding and to have access to and be
consulted in connection with any document, opinion or proposal made or submitted to any Governmental Body in connection with any such Legal Proceeding. The Company and Parent shall (upon request)
promptly deliver to the other party a copy of each such filing made, each such notice given and each such Consent obtained by the Company or Parent, as the case may be, during the
Pre-Closing Period. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;5.2&nbsp;&nbsp;Sale of Parent Common Stock; Shareholder's Certificates.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;The parties hereto acknowledge and agree
that the shares of Parent Common Stock issuable to the Company's shareholders pursuant to Section&nbsp;1.5 hereof shall constitute "restricted securities" within the meaning of Rule&nbsp;144 under
the Securities Act. The certificates for shares of Parent Common Stock to be issued in the Merger shall </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>28</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=3,SEQ=35,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=642912,FOLIO='28',FILE='DISK016:[01PAL5.01PAL2055]KM2055A.;6',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<A NAME="page_km2055_1_29"> </A>

<P><FONT SIZE=2>
bear appropriate legends to identify such privately placed shares as being restricted under the Securities Act, to comply with applicable state securities laws and, if applicable, to notice the
restrictions on transfer pursuant to the Lock-Up Agreement (as defined below). It is acknowledged and understood that Parent is relying upon certain written representations made by each
shareholder. The Company will use its best efforts to cause each shareholder of the Company to execute and deliver to Parent a Shareholder's Certificate in the form attached hereto as
Exhibit&nbsp;D. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;5.3&nbsp;&nbsp;Company Shareholders' Consent.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;The Company shall, in accordance with its articles of incorporation
and bylaws and the applicable requirements of the Alabama Business Corporation Act, call and hold a special meeting of its shareholders as promptly as practicable for the purpose of permitting them to
consider and to vote upon and approve the Merger and this Agreement (the "Company Shareholders' Meeting"). Without limiting the generality or the effect of anything contained in the Shareholder
Agreement being executed and delivered by the Signing Shareholders to Parent contemporaneously with the execution and delivery of this Agreement, the Signing Shareholders shall cause all shares of the
capital stock of the Company that are owned, beneficially or of record, by the Signing Shareholders
on the record date for the Company Shareholders' Meeting to be voted in favor of the Merger and this Agreement at such meeting. For greater certainty, in lieu of calling and holding a special
shareholders' meeting, the Company may solicit the approval of the shareholders of the Company of the Merger and the other transactions contemplated by this Agreement by written consent. In any event,
the Company shall solicit by written consent, or hold a special meeting of shareholders, for the purpose of voting upon the approval and adoption of the Merger and this Agreement no later than
30&nbsp;days after the date of this Agreement. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;5.4&nbsp;&nbsp;Public Announcements.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;During the Pre-Closing Period, (a)&nbsp;neither the Company nor
the Signing Shareholders shall (and the Company shall not permit any of its Representatives to) issue any press release or make any public statement regarding this Agreement or the Merger, or
regarding any of the other transactions contemplated by this Agreement, without Parent's prior written consent, and (b)&nbsp;Parent will use reasonable efforts to consult with the Company prior to
issuing any press release or making any public statement regarding the Merger. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;5.5&nbsp;&nbsp;Best Efforts.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;During the Pre-Closing Period, (a)&nbsp;the Company and the Signing
Shareholders shall use their best efforts to cause the conditions set forth in Section&nbsp;6 to be satisfied on a timely basis (including, without limitation, to cure any inaccuracy in any
representation or warranty that could exist as of the Scheduled Closing Time), and (b)&nbsp;Parent and Merger Sub shall use their best efforts to cause the conditions set forth in Section&nbsp;7
to be satisfied on a timely basis (including, without limitation, to cure any inaccuracy in any representation or warranty that could exist as of the Scheduled Closing Time). </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;5.6&nbsp;&nbsp;Tax Matters.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Prior to the Closing, Parent and the Company shall execute and deliver to Cooley
Godward LLP, tax representation letters in substantially the form of Exhibit&nbsp;D (which will be used in connection with the legal opinion contemplated by Section&nbsp;6.5(l)). </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;5.7&nbsp;&nbsp;Employment and Noncompetition Agreements.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;At or prior to the Closing, J. Milton Harris shall
execute and deliver to the Surviving Corporation and Parent an Employment Agreement in substantially the form of Exhibit&nbsp;G-1 and a Noncompetition Agreement in substantially the form
of Exhibit&nbsp;H-1, and Michael Bentley shall execute and deliver to the Surviving Corporation and Parent an Employment Agreement in substantially the form of
Exhibit&nbsp;G-2 and a Noncompetition Agreement in substantially the form of Exhibit&nbsp;H-2. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;5.8&nbsp;&nbsp;Lock-Up Agreement.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;At or prior to the Closing, each of the Designated Shareholders
shall execute and deliver to Parent a Lock-Up Agreement in substantially the form of Exhibit&nbsp;I. </FONT></P>


<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;5.9&nbsp;&nbsp;Employee Related Matters.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Parent shall offer to employees of the Company as of the date of this
Agreement who are also employees of the Company immediately prior to the Effective Time </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>29</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=4,SEQ=36,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=1039792,FOLIO='29',FILE='DISK016:[01PAL5.01PAL2055]KM2055A.;6',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<A NAME="page_km2055_1_30"> </A>

<P><FONT SIZE=2>
employment by the Parent or Merger Sub after the Effective Time, and each such offer shall be in the form of an individual offer letter prepared in accordance with Parent's customary form (such letter
to confirm such employee's initial position, compensation, location and reporting relationship). Those employees of the Company that continue to be employees of Parent or any of its affiliates,
including the Merger Sub, following the Closing shall, subject to any necessary transition period and the terms of such plans, be immediately eligible to participate in Parent's health, vacation,
employee stock purchase, 401(k) and other plans, to the same extent as comparably situated employees of Parent and shall receive credit under all Parent's benefit plans for time served as an employee
of the Company (it being agreed that such credit shall not apply with respect to the vesting schedule of any stock options granted by Parent to such employees other than Company Options assumed by the
Parent pursuant to Section&nbsp;1.6). </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;5.10&nbsp;&nbsp;Tax-Free Reorganization.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;No party shall take any action either prior to or after the
Effective Time that could reasonably be expected to cause the Merger to fail to qualify as a "reorganization" under Section&nbsp;368 of the Code. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;5.11&nbsp;&nbsp;FIRPTA Matters.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;At the Closing, (a)&nbsp;the Company shall deliver to Parent a statement (in
such form as may be reasonably requested by counsel to Parent) conforming to the requirements of Section&nbsp;1.897&nbsp;-&nbsp;2(h)(1)(i)&nbsp;of the United States Treasury
Regulations, and (b)&nbsp;the Company shall deliver to the Internal Revenue Service the notification required under Section&nbsp;1.897&nbsp;-&nbsp;2(h)(2) of the United States
Treasury Regulations. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;5.12&nbsp;&nbsp;Release.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;At the Closing, each of the shareholders of the Company shall execute and deliver to the
Parent, Merger Sub and Company a Release in substantially the form of Exhibit&nbsp;K. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;5.13&nbsp;&nbsp;Termination of Employee Plans.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;The Company shall terminate, effective as of the day immediately
preceding the Closing Date, conditioned upon Closing, any and all 401(k) plans or other pension plans (the "401(k) Plan") sponsored or maintained by Company unless Parent provides written notice to
Company prior to the day immediately preceding the Closing Date that any such 401(k) Plan shall not be terminated. Company shall provide Parent written evidence that the 401(k) Plan has been
terminated pursuant to resolutions of Company's Board of Directors (the form and substance of such resolutions shall be subject to review and approval of Parent), effective as of the day immediately
preceding the Closing Date. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;5.14&nbsp;&nbsp;Title Insurance.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Prior to the Closing, the Company shall obtain an ALTA owner's policy of title
insurance to the Company's benefit in such amounts and on such terms as reasonably consented to by Parent, with respect to the Company's property at Discovery Drive, Huntsville, Alabama. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;5.15&nbsp;&nbsp;Amendment of Consulting Contracts.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Prior to the Closing, the Company shall take commercially
reasonable efforts to amend all outstanding Contracts with Dr.&nbsp;Thomas P. Davis and Dr.&nbsp;Marshall Schreeder on such terms as are reasonably acceptable to Parent (the "Schreeder/Davis
Amendments"), which agreements, as so amended, will be in full force and effect as of the Effective Time. </FONT></P>

<P><FONT SIZE=2><B>SECTION 6. CONDITIONS PRECEDENT TO OBLIGATIONS OF PARENT AND MERGER SUB  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The obligations of Parent and Merger Sub to effect the Merger and otherwise consummate the transactions contemplated by this Agreement are subject to the
satisfaction, at or prior to the Closing, of each of the following conditions: </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;6.1&nbsp;&nbsp;Accuracy of Representations.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Each of the representations and warranties made by the Company and the
Signing Shareholders in this Agreement and in each of the other agreements and instruments delivered to Parent in connection with the transactions contemplated by this Agreement shall have been
accurate in all material respects as of the date of this Agreement (without giving effect to any "Material Adverse Effect" or other materiality qualifications, or any similar qualifications, </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>30</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=5,SEQ=37,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=721925,FOLIO='30',FILE='DISK016:[01PAL5.01PAL2055]KM2055A.;6',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<A NAME="page_km2055_1_31"> </A>

<P><FONT SIZE=2>
contained or incorporated directly or indirectly in such representations and warranties), and shall be accurate in all material respects as of the Scheduled Closing Time as if made at the Scheduled
Closing Time (without giving effect to any update to the Disclosure Schedule, and without giving effect to any "Material Adverse Effect" or other materiality qualifications, or any similar
qualifications, contained or incorporated directly or indirectly in such representations and warranties). </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;6.2&nbsp;&nbsp;Performance of Covenants.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;All of the covenants and obligations that the Company and the Signing
Shareholders are required to comply with or to perform at or prior to the Closing shall have been complied with and performed in all respects. </FONT></P>


<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;6.3&nbsp;&nbsp;Shareholder Approval.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;The principal terms of the Merger shall have been duly approved by the
affirmative vote of 100% of the shares of Company Common Stock entitled to vote with respect thereto. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;6.4&nbsp;&nbsp;Consents.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;All Consents required to be obtained in connection with the Merger and the other
transactions contemplated by this Agreement by the Company or Designated Shareholders (including the Consents identified in Part&nbsp;2.21 of the Disclosure Schedule) shall have been obtained and
shall be in full force and effect. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;6.5&nbsp;&nbsp;Agreements and Documents.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Parent and the Surviving Corporation shall have received the following
agreements and documents, each of which shall be in full force and effect: </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2>&nbsp;An Escrow Agreement in substantially the form of Exhibit&nbsp;C, executed by the Shareholders' Agent and the other
parties thereto, and the Escrow Consideration shall have been deposited thereunder; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2>&nbsp;Shareholder's Certificates in substantially the form of Exhibit&nbsp;D, executed by each of the Company's
shareholders; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(c)</B></FONT><FONT SIZE=2>&nbsp;Employment Agreements in substantially the form of Exhibit&nbsp;G-1 or G-2, executed by
the appropriate individuals identified on Exhibit&nbsp;F; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(d)</B></FONT><FONT SIZE=2>&nbsp;Noncompetition Agreements in substantially the form of Exhibit&nbsp;H-1 or H-2, executed
by the appropriate individuals identified on Exhibit&nbsp;F; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(e)</B></FONT><FONT SIZE=2>&nbsp;a Lock-Up Agreement in substantially the form of Exhibit&nbsp;I, executed by each of the Designated
Shareholders; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(f)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;a Registration Rights Agreement in substantially the form of Exhibit&nbsp;J, executed by each of the shareholders
of the Company; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(g)</B></FONT><FONT SIZE=2>&nbsp;a Release in substantially the form of Exhibit&nbsp;K, executed by each of the shareholders of the Company; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(h)</B></FONT><FONT SIZE=2>&nbsp;confidential invention and assignment agreements (containing no exceptions or exclusions as to the scope of
coverage) in substantially the form provided to Parent on or prior to the date of this Agreement, executed by all current employees, consultants and independent contractors of the Company who have not
already signed such agreements and who are involved in or contributed to, the creation or development of any Company Proprietary Asset (including all individuals identified in Part&nbsp;2.9(b) of
the Disclosure Schedule); </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(i)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;the statement referred to in Section&nbsp;5.11(a), executed by the Company; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(j)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;an estoppel certificate, dated as of a date not more than five days prior to the Closing Date and satisfactory in
form and content to Parent, executed by Shearwater Polymers, LLC; </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(k)</B></FONT><FONT SIZE=2>&nbsp;a legal opinion of Bradley, Arant, Rose&nbsp;&amp; White LLP, in a form reasonably acceptable to Parent, with respect
to the matters set forth on Exhibit&nbsp;L; </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>31</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=6,SEQ=38,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=189787,FOLIO='31',FILE='DISK016:[01PAL5.01PAL2055]KM2055B.;5',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<A NAME="page_km2055_1_32"> </A>

<P><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>(l)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;a legal opinion of Cooley Godward LLP in substantially the form set forth as Exhibit&nbsp;Q (or a similar opinion
of such other counsel as may be reasonably agreed to by Parent and the Company in such form as may be reasonably agreed to by Parent and the Company), dated as of the Closing Date, to the effect that
the Merger will constitute a reorganization within the meaning of Section&nbsp;368 of the Code (it being understood that, in rendering such opinion, such counsel may rely upon the tax representation
letter referred to in Section&nbsp;5.6); </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(m)</B></FONT><FONT SIZE=2>&nbsp;a certificate executed by the Chief Executive Officer of the Company and the Designated Shareholders and containing
the representation and warranty of the Company and the Designated Shareholders that each of the representations and warranties set forth in Section&nbsp;2 is accurate in all material respects as of
the Closing Date as if made on the Closing Date (without giving effect to any "Material Adverse Effect" or other materiality qualifications, or any similar qualifications, contained or incorporated
directly or indirectly in such representations and warranties) and that the conditions set forth in Sections 6.1, 6.2, 6.3 and 6.4 have been duly satisfied (the "Closing Certificate"); </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(n)</B></FONT><FONT SIZE=2>&nbsp;written resignations of all directors of the Company, effective as of the Effective Time; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(o)</B></FONT><FONT SIZE=2>&nbsp;the letter agreement dated May&nbsp;14, 2001 in the form provided by the Company to Parent, executed by the
Company and Professor Francesco Veranese; and </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(p)</B></FONT><FONT SIZE=2>&nbsp;the letter agreement, in substantially the form set forth as Exhibit&nbsp;P, executed by Simon Pedder; and </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(q)</B></FONT><FONT SIZE=2>&nbsp;the Schreeder/Davis Amendments. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;6.6&nbsp;&nbsp;FIRPTA Compliance.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;The Company shall have filed with the Internal Revenue Service the notification
referred to in Section&nbsp;5.11(b). </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;6.7&nbsp;&nbsp;Blue Sky Compliance.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Parent shall have obtained all necessary blue sky law permits and
qualifications, or have the availability of exemptions therefrom, required by any state for the issuance of the Parent Common Stock pursuant to this Agreement. </FONT></P>


<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;6.8&nbsp;&nbsp;HSR Act.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;The waiting period applicable to the consummation of the Merger under the HSR Act shall
have expired or been terminated. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;6.9&nbsp;&nbsp;Listing.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;The shares of Parent Common Stock to be issued in the Merger shall have been approved for
listing (subject to notice of issuance) on the Nasdaq National Market. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;6.10&nbsp;&nbsp;No Restraints.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;No temporary restraining order, preliminary or permanent injunction or other order
preventing the consummation of the Merger shall have been issued by any court of competent jurisdiction and remain in effect, and there shall not be any Legal Requirement enacted or deemed applicable
to the Merger that makes consummation of the Merger illegal. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;6.11&nbsp;&nbsp;No Legal Proceedings.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;No Person shall have commenced or threatened to commence any Legal
Proceeding challenging or seeking the recovery of a material amount of damages in connection with the Merger or seeking to prohibit or limit the exercise by Parent of any material right pertaining to
its ownership of stock of the Surviving Corporation. </FONT></P>


<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;6.12&nbsp;&nbsp;Employees.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;None of the individuals identified on Exhibit&nbsp;M shall have ceased to be employed
by, or expressed an intention to terminate their employment with, the Company. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;6.13&nbsp;&nbsp;Termination of Employee Plans.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;The Company shall have provided Parent with evidence, reasonably
satisfactory to Parent, as to the termination of the benefit plans referred to in Section&nbsp;5.13. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;6.14&nbsp;&nbsp;Amendment of Real Property Lease.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Shearwater Polymers, LLC and the Company shall amended and
restated the Lease Agreement dated May&nbsp;27, 1999, by and between Shearwater Polymers, LLC and the Company to provide for the matters described in Part&nbsp;6.15 of the Disclosure Schedule. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>32</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=7,SEQ=39,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=82979,FOLIO='32',FILE='DISK016:[01PAL5.01PAL2055]KM2055B.;5',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<A NAME="page_km2055_1_33"> </A>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;6.15&nbsp;&nbsp;Payment of Receivable.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Shearwater Polymers, LLC shall have repaid (without any requirement of
additional capital contributions to Shearwater Polymers, LLC by the Company) all accrued interest and outstanding principal on the note receivable held by the Company in principal amount of
$243,867.27, dated as of March&nbsp;31, 2001. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;6.16&nbsp;&nbsp;No issuance of Capital Stock.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;The Company shall not, since the date of this Agreement, have issued
or authorized the issuance of (i)&nbsp;any capital stock or other security, (ii)&nbsp;any option or right to acquire any capital stock or other security, or (iii)&nbsp;any instrument convertible
into or exchangeable for any capital stock or other security. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;6.17&nbsp;&nbsp;No Material Adverse Change.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;There shall have been no event, violation, inaccuracy, circumstance or
other matter that constitutes a Material Adverse Effect on the Company. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;6.18&nbsp;&nbsp;Shareholder Approval of Option Acceleration.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;The shareholders of the Company shall have approved
the acceleration of the Company Options under the Company's 1996 Nonqualified Stock Option Plan in accordance with Section&nbsp;280G of the Internal Revenue Code and the regulations thereunder. </FONT></P>

<P><FONT SIZE=2><B>SECTION 7. CONDITIONS PRECEDENT TO OBLIGATIONS OF THE COMPANY  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The obligations of the Company to effect the Merger and otherwise consummate the transactions contemplated by this Agreement are subject to the satisfaction,
at or prior to the Closing, of the following conditions: </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;7.1&nbsp;&nbsp;Accuracy of Representations.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Each of the representations and warranties made by Parent and Merger
Sub in this Agreement shall have been accurate in all material respects as of the date of this Agreement (without giving effect to any materiality or similar qualifications contained in such
representations and warranties), and shall be accurate in all material respects as of the Scheduled Closing Time as if made at the Scheduled Closing Time (without giving effect to any materiality or
similar qualifications contained in such representations and warranties). </FONT></P>


<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;7.2&nbsp;&nbsp;Performance of Covenants.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;All of the covenants and obligations that Parent and Merger Sub are
required to comply with or to perform at or prior to the Closing shall have been complied with and performed in all respects. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;7.3&nbsp;&nbsp;No Restraints.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;No temporary restraining order, preliminary or permanent injunction or other order
preventing the consummation of the Merger shall have been issued by any court of competent
jurisdiction and remain in effect, and there shall not be any Legal Requirement enacted or deemed applicable to the Merger that makes consummation of the Merger illegal. </FONT></P>


<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;7.4&nbsp;&nbsp;Consents.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;All Consents required to be obtained in connection with the Merger and the other
transactions contemplated by this Agreement by Parent and Merger Sub shall have been obtained and shall be in full force and effect. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;7.5&nbsp;&nbsp;Agreements and Documents.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;The Company shall have received the following agreements and documents,
each of which shall be in full force and effect: </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2>&nbsp;a Registration Rights Agreement in the form of Exhibit&nbsp;J, executed by Parent. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2>&nbsp;a certificate executed by the Chief Executive Officer of the Parent and containing the representation and warranty
of the Parent that each of the representations and warranties set forth in Section&nbsp;3 is accurate in all material respects as of the Closing Date as if made on the Closing Date (without giving
effect to any "Material Adverse Effect" or other materiality qualifications, or any similar qualifications, contained or incorporated directly or indirectly in such representations and warranties) and
that the conditions set forth in Sections 7.1, 7.2, 7.3 and 7.4 have been duly satisfied; </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>33</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=8,SEQ=40,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=734649,FOLIO='33',FILE='DISK016:[01PAL5.01PAL2055]KM2055B.;5',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<A NAME="page_km2055_1_34"> </A>

<P><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>(c)</B></FONT><FONT SIZE=2>&nbsp;Employment Agreements in the form of Exhibit&nbsp;G, with respect to the individuals identified on
Exhibit&nbsp;F, executed by Merger Sub; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(d)</B></FONT><FONT SIZE=2>&nbsp;a legal opinion of Cooley Godward LLP, in a form reasonably acceptable to the Company, dated as of the Closing Date,
with respect to the matters set forth on Exhibit&nbsp;N (it being understood and agreed that Cooley Godward LLP may rely on Alabama counsel with respect to matters of Alabama law); and </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(e)</B></FONT><FONT SIZE=2>&nbsp;a legal opinion of the general counsel to Parent, in a form reasonably acceptable to the Company, dated as of the
Closing Date, with respect to the matters set forth on Exhibit&nbsp;O. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;7.6&nbsp;&nbsp;HSR Act.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;The waiting period applicable to the consummation of the Merger under the HSR Act shall
have expired or been terminated. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;7.7&nbsp;&nbsp;Listing.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;The shares of Parent Common Stock to be issued in the Merger shall have been approved for
listing (subject to notice of issuance) on the Nasdaq National Market. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;7.8&nbsp;&nbsp;Tax Opinion.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;The Company shall have received a copy of the executed legal opinion of Cooley Godward
LLP to Parent in substantially the form set forth as Exhibit&nbsp;Q (or a similar opinion of such other counsel as may be reasonably agreed to by Parent and the Company in such form as may be
reasonably agreed to by Parent and the Company), dated as of the Closing Date to the effect that the Merger will constitute a reorganization within the meaning of Section&nbsp;368 of the Code (it
being understood that, in rendering such opinion, such counsel may rely upon the tax representation letter referred to in Section&nbsp;5.6); provided, however, that in no case shall this condition
be met if the Cash Consideration shall exceed 55% of the Merger Consideration as of the Closing Date. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;7.9&nbsp;&nbsp;Payment of Consideration.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;The Cash Consideration to be paid to the Company's shareholders shall
have been wire transferred to the Escrow Agent and, except with respect to the Escrowed Cash, distributed in accordance with the Escrow Agreement. </FONT></P>

<P><FONT SIZE=2><B>SECTION 8. TERMINATION  </B></FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;8.1&nbsp;&nbsp;Termination Events.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;This Agreement may be terminated prior to the Closing: </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2>&nbsp;by Parent at or after the Scheduled Closing Time if any condition set forth in Section&nbsp;6 has not been
satisfied by the Scheduled Closing Time; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2>&nbsp;by the Company at or after the Scheduled Closing Time if any condition set forth in Section&nbsp;7 has not been
satisfied by the Scheduled Closing Time; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(c)</B></FONT><FONT SIZE=2>&nbsp;by Parent if the Closing has not taken place on or before July&nbsp;31, 2001 or such later date as mutually agreed
to by Parent and the Company (other than as a result of any failure on the part of Parent to comply with or perform any covenant or obligation of Parent set forth in this Agreement); </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(d)</B></FONT><FONT SIZE=2>&nbsp;by the Company if the Closing has not taken place on or before July&nbsp;31, 2001 or such later date as mutually
agreed to by Parent and the Company (other than as a result of the failure on the part of the Company or the Signing Shareholders to comply with or perform any covenant or obligation set forth in this
Agreement or in any other agreement or instrument delivered to Parent); </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(e)</B></FONT><FONT SIZE=2>&nbsp;by the mutual consent of Parent and the Company; or </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(f)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;by either Parent or the Company if a court of competent jurisdiction or other Governmental Body shall have issued a
final and non-appealable order, decree, or ruling or shall have taken any other action, having the effect of permanently restraining, enjoining or otherwise prohibiting the Merger. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>34</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=9,SEQ=41,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=504104,FOLIO='34',FILE='DISK016:[01PAL5.01PAL2055]KM2055B.;5',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->

<P><FONT SIZE=2><A
NAME="page_ko2055_1_35"> </A> </FONT> <FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;8.2&nbsp;&nbsp;Termination Procedures.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;If Parent wishes to terminate this Agreement pursuant to
Section&nbsp;8.1(a) or Section&nbsp;8.1(c), Parent shall deliver to the Company a written notice stating that Parent is terminating this Agreement and setting forth a brief description of the
basis on which Parent is terminating this Agreement. If the Company wishes to terminate this Agreement pursuant to Section&nbsp;8.1(b) or Section&nbsp;8.1(d), the Company shall deliver to Parent a
written notice stating that the Company is terminating this Agreement and setting forth a brief description of the basis on which the Company is terminating this Agreement. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;8.3&nbsp;&nbsp;Effect of Termination.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;If this Agreement is terminated pursuant to Section&nbsp;8.1, this
Agreement shall be of no further force or effect (and, except as provided in this Section&nbsp;8.3, there shall be no liability or obligation hereunder on the part of any of the parties hereto or
their respective officers, directors, stockholders or affiliates); </FONT><FONT SIZE=2><I>provided, however,</I></FONT><FONT SIZE=2> that this Section&nbsp;8.3 and Section&nbsp;10 shall survive
the termination of this Agreement and shall remain in full force and effect, and the termination of this Agreement shall not relieve any party from any liability for any willful breach of any
representation, warranty or covenant contained in this Agreement. </FONT></P>

<P><FONT SIZE=2><B>SECTION 9. INDEMNIFICATION, ETC.  </B></FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;9.1&nbsp;&nbsp;Survival of Representations, Etc.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;</FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2>&nbsp;The representations and warranties made by the Company and Designated Shareholders (including the representations
and warranties set forth in Section&nbsp;2 and the representations and warranties set forth in the Closing Certificate) shall survive the Closing and shall expire on the date eighteen
(18)&nbsp;months following the Closing Date </FONT><FONT SIZE=2><I>provided, however</I></FONT><FONT SIZE=2>, that the representations and warranties set forth in Section&nbsp;2.14 hereof shall
not expire until all applicable statutes of limitations with respect to the matters covered by Section&nbsp;2.14 have expired; </FONT><FONT SIZE=2><I>provided, further,</I></FONT><FONT SIZE=2> that
if, at any time prior to the respective expiration dates set forth above, any Indemnitee (acting in good faith) delivers to the Shareholders' Agent (as defined below) a written notice alleging the
existence of an inaccuracy in or a breach of any of the representations and warranties made by the Company and Designated Shareholders (and setting forth in reasonable detail the basis for such
Indemnitee's belief that such an inaccuracy or breach may exist) and asserting a claim for recovery under Section&nbsp;9.2 based on such alleged inaccuracy or breach, then the claim asserted in such
notice shall survive the expiration dates set forth above until such time as such claim is fully and finally resolved. The representations and warranties made by Parent and Merger Sub shall terminate
and expire as of the Effective Time, and any liability of Parent or Merger Sub with respect to such representations and warranties shall
thereupon cease; </FONT><FONT SIZE=2><I>provided, however,</I></FONT><FONT SIZE=2> that the representatives and warranties set forth in Section&nbsp;3.4 hereof shall not expire and shall survive
the Closing. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2>&nbsp;Except as set forth in 9.2(f), the representations, warranties made by the Company and Designated Shareholders, and
the covenants and obligations of the Company and Designated Shareholders, and the rights and remedies that may be exercised by the Indemnitees, shall not be limited or otherwise affected by or as a
result of any information furnished to, or any investigation made by or knowledge of, any of the Indemnitees or any of their Representatives. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(c)</B></FONT><FONT SIZE=2>&nbsp;Notwithstanding the provisions of Section&nbsp;9.2(a), in the event of intentional fraud any claim for such
intentional fraud, shall survive until the expiration of all applicable statutes of limitations (including all periods of extension, whether automatic or permissive) with respect to such fraud claim. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;9.2&nbsp;&nbsp;Indemnification by Shareholders.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;</FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2>&nbsp;From and after the Effective Time (but subject to Section&nbsp;9.1), the shareholders of the Company who shall
have received, or shall be entitled to receive, Parent Common Stock and/or cash payments pursuant to Section&nbsp;1.5 (the "Indemnitors"), severally but not jointly, shall hold harmless and
indemnify each of the Indemnitees from and against, and shall compensate and reimburse (which </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>35</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=42,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=982010,FOLIO='35',FILE='DISK016:[01PAL5.01PAL2055]KO2055A.;4',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<A NAME="page_ko2055_1_36"> </A>

<P><FONT SIZE=2>
compensation and reimbursement, except in the event of intentional fraud or breaches of representations and warranties set forth in Section&nbsp;2.14, shall be solely from and out of the Escrow
Consideration) each of the Indemnitees for, (i)&nbsp;any Damages which are directly or indirectly suffered or incurred by any of the Indemnitees or to which any of the Indemnitees may otherwise
become subject (regardless of whether or not such Damages relate to any third-party claim) and which arise from or as a result of, or are directly or indirectly connected with: (A)&nbsp;any
inaccuracy in or breach of any representation or warranty set forth in Section&nbsp;2 or the Closing Certificate (without giving effect to any "Material Adverse Effect" or other materiality
qualification or any similar qualification contained or incorporated directly or indirectly in such representation or warranty, but with giving effect to any update to the Disclosure Schedule
delivered by the Company to Parent prior to the Closing) to the extent such representation and warranty has not expired pursuant to Section&nbsp;9.1 above; and (B)&nbsp;any breach of any covenant
or obligation of the Company (including the covenants set forth in Sections 4 and 5); (ii)&nbsp;any Legal Proceeding relating to any inaccuracy or breach of the type referred to in clause "(A)", or
"(B)" above (including any Legal Proceeding commenced by any Indemnitee for the purpose of enforcing any of its rights under this Section&nbsp;9). The indemnities contained in this
Section&nbsp;9.2 shall expire on the date 18&nbsp;months following the Closing Date, except (i)&nbsp;with respect to which a notice of an inaccuracy in or a breach of any of the representations
and warranties or breach of any covenant or obligation shall have been provided, (ii)&nbsp;with respect to intentional fraud; and (iii)&nbsp;with respect to breaches of the representations and
warranties set forth in Section&nbsp;2.14 herein. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2>&nbsp;The Company acknowledges and agrees that, if the Surviving Corporation suffers, incurs or otherwise becomes subject
to any Damages as a result of or in connection with any inaccuracy in or breach of any representation, warranty, covenant or obligation, then (without limiting any of the rights of the Surviving
Corporation as an Indemnitee) Parent shall also be deemed, by virtue of its ownership of the stock of the Surviving Corporation, to have incurred Damages as a result of and in connection with such
inaccuracy or breach. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(c)</B></FONT><FONT SIZE=2>&nbsp;The Indemnitors shall not be required to make any indemnification payment pursuant to
Section&nbsp;9.2(a)(i)&nbsp;or (ii)&nbsp;until such time as the total amount of all Damages (including the Damages arising from any inaccuracies in or breaches of any representations or
warranties) that have been directly or indirectly suffered or incurred by any one or more of the Indemnitees, or to which any one or more of the Indemnitees has or have otherwise become subject,
exceeds $500,000 in the aggregate (the "Damages Threshold"); provided, however, if the total amount of such Damages exceeds the Damages Threshold, then the Indemnitees shall be entitled to be
indemnified against and compensated and reimbursed for any and all Damages regardless of the Damages Threshold. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(d)</B></FONT><FONT SIZE=2>&nbsp;Notwithstanding anything to the contrary set forth in this Agreement, the maximum liability of each Indemnitor to
the Indemnitees for Damages relating to any breach by the Company or Designated Shareholders of any representation or warranty, covenant or other provision contained in this Agreement shall be limited
to an amount equal to and, except in the event of intentional fraud or breaches of the representations and warranties set forth in Section&nbsp;2.14, payable solely out of the Escrow Consideration
held in the name of such Indemnitor pursuant to Section&nbsp;1.8; </FONT><FONT SIZE=2><I>provided, however,</I></FONT><FONT SIZE=2>that the limitation with respect to the amount of liability to
which any Indemnitor may become subject that are set forth in this Section&nbsp;9.2(d) shall not apply in the case of intentional fraud. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(e)</B></FONT><FONT SIZE=2>&nbsp;Notwithstanding anything to the contrary set forth in this Agreement, the indemnity provided in this
Section&nbsp;9 shall be the sole and exclusive remedy of the Indemnitees for Damages relating to any breach by the Company or Designated Shareholders of any representation or warranty, covenant or
other provision contained in this Agreement; </FONT><FONT SIZE=2><I>provided, however,</I></FONT><FONT SIZE=2> that the limitations set forth in this Section&nbsp;9.2(e) shall not apply in the case
of intentional fraud. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(f)</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Notwithstanding anything to the contrary set forth in this Agreement, the Indemnitees shall not be entitled to
indemnification under this Section&nbsp;9 which arises out of facts and circumstances </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>36</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=43,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=934082,FOLIO='36',FILE='DISK016:[01PAL5.01PAL2055]KO2055A.;4',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<A NAME="page_ko2055_1_37"> </A>

<P><FONT SIZE=2>
specifically disclosed on the Disclosure Schedule, any update to the Disclosure Schedule delivered prior to Closing or the Company Closing Certificate and not be entitled to indemnification under this
Section&nbsp;9 for any Tax liability incurred by Company arising from: (i)&nbsp;any merger, liquidation, business combination or other structural change to the Company made by or on behalf of
Parent or Merger Sub on or after the Closing Date, (ii)&nbsp;any Tax election(s) made by or on behalf of Parent or Merger Sub
immediately before, on or after the Closing Date, or (iii)&nbsp;any Taxes incurred by the operation of the Company's business by Parent or Merger Sub after the Closing Date. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(g)</B></FONT><FONT SIZE=2>&nbsp;The parties each agree to use their commercially reasonable efforts to mitigate any Damages which are subject to
indemnification hereunder. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;9.3&nbsp;&nbsp;No Contribution.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Each Indemnitor waives, and acknowledges and agrees that he shall not have and
shall not exercise or assert (or attempt to exercise or assert), any right of contribution, right of indemnity or other right or remedy against the Surviving Corporation in connection with any
indemnification obligation or any other liability to which he may become subject under or in connection with this Agreement or the Closing Certificate. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;9.4&nbsp;&nbsp;Interest.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Any Indemnitor who is required to hold harmless, indemnify, compensate or reimburse any
Indemnitee pursuant to this Section&nbsp;9 with respect to any Damages shall also be liable to such Indemnitee for interest on the amount of such Damages (for the period commencing as of the date on
which such Indemnitor first received notice of a claim for recovery by such Indemnitee and ending on the date on which the liability of such Indemnitor to such Indemnitee is fully satisfied by such
Indemnitor) at a floating rate equal to the rate of interest publicly announced by Bank of America, N.T.&nbsp;&amp; S.A. from time to time as its prime, base or reference rate. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;9.5&nbsp;&nbsp;Defense of Third Party Claims.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;In the event of the assertion or commencement by any Person of any
claim or Legal Proceeding (whether against Merger Sub, the Company, Parent or against any other Person) with respect to which any Indemnitor may become obligated to hold harmless, indemnify,
compensate or reimburse any Indemnitee pursuant to this Section&nbsp;9, Parent shall have the right, at its election, to proceed with the defense of such claim or Legal Proceeding on its own with
counsel reasonably satisfactory to the Shareholders' Agent; </FONT><FONT SIZE=2><I>provided, however,</I></FONT><FONT SIZE=2> that the Shareholders' Agent may retain separate co-counsel
at its sole cost and expense and participate in the defense of such claim or Legal Proceeding. If Parent so proceeds with the defense of any such claim or Legal Proceeding: </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2>&nbsp;all reasonable expenses relating to the defense of such claim or Legal Proceeding shall be borne and paid
exclusively by the Indemnitors; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2>&nbsp;each Indemnitor shall make available to Parent any documents and materials in his possession or control that may be
necessary to the defense of such claim or Legal Proceeding; and </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(c)</B></FONT><FONT SIZE=2>&nbsp;Parent shall have the right to settle, adjust or compromise such claim or Legal Proceeding with the consent of the
Shareholders' Agent (as defined in Section&nbsp;10.1); provided, however, that such consent shall not be unreasonably withheld. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Parent
shall give the Shareholders' Agent prompt notice of the commencement of any such Legal Proceeding against Parent or the Surviving Corporation and shall keep the Shareholders'
Agent informed at all stages thereof; provided, however, that any failure on the part of Parent to so notify or inform the Shareholders' Agent shall not limit any of the obligations of the Indemnitors
under this Section&nbsp;9 (except to the extent such failure materially prejudices the defense of such Legal Proceeding). </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;9.6&nbsp;&nbsp;Exercise of Remedies by Indemnitees Other Than Parent.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;No Indemnitee (other than Parent or any
successor thereto or assign thereof) shall be permitted to assert any indemnification claim or exercise any other remedy under this Agreement unless Parent (or any successor thereto or assign </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>37</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=3,SEQ=44,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=423972,FOLIO='37',FILE='DISK016:[01PAL5.01PAL2055]KO2055A.;4',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<A NAME="page_ko2055_1_38"> </A>

<P><FONT SIZE=2>
thereof) shall have consented in writing to the assertion of such indemnification claim or the exercise of such other remedy. </FONT></P>

<P><FONT SIZE=2><B>SECTION 10. MISCELLANEOUS PROVISIONS  </B></FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;10.1&nbsp;&nbsp;Designated Shareholders' Agent.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;By virtue of their approval of the Merger, the shareholders of the
Company hereby irrevocably appoint J. Milton Harris as their agent for purposes of Section&nbsp;9 (the "Shareholders' Agent"), and J. Milton Harris hereby accepts his appointment as the
Shareholders' Agent. Parent shall be entitled to deal exclusively with the Shareholders' Agent on all matters relating to Section&nbsp;9, and shall be entitled to rely conclusively (without further
evidence of any kind whatsoever) on any document executed or purported to be executed on behalf of any Company Shareholder by the Shareholders' Agent, and on any other action taken or purported to be
taken on behalf of any Company Shareholder by the Shareholders' Agent, as fully binding upon such Company Shareholder. If the Shareholders' Agent shall die, become disabled or otherwise be unable to
fulfill his responsibilities as agent of the Company Shareholders, then the Company Shareholders shall, within ten days after such death or disability, appoint a successor agent and, promptly
thereafter, shall notify Parent of the identity of such successor. Any such successor shall become the "Shareholders' Agent" for purposes of Section&nbsp;9 and this Section&nbsp;10.1. </FONT></P>


<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;10.2&nbsp;&nbsp;Further Assurances.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Each party hereto shall execute and cause to be delivered to each other party
hereto such instruments and other documents, and shall take such other actions, as such other party may reasonably request (prior to, at or after the Closing) for the purpose of carrying out or
evidencing any of the transactions contemplated by this Agreement. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;10.3&nbsp;&nbsp;Fees and Expenses.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;</FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2>&nbsp;Except as provided in Section&nbsp;10.3(b), Parent and the Company agree that each party to this Agreement shall
bear and pay its respective fees, costs and expenses (including legal fees and accounting fees) that have been incurred or that are incurred by such party in connection with the transactions
contemplated by this Agreement, including all fees, costs, and expenses incurred by such party in connection with or by virtue of (a)&nbsp;the investigation and review conducted by Parent and its
Representatives with respect to the Company's business (and the furnishing of information to Parent and its Representatives in connection with such investigation and review), (b)&nbsp;the
negotiation, preparation and review of this Agreement (including the Disclosure Schedule) and all agreements, certificates, opinions and other instruments and documents delivered or to be delivered in
connection with the transactions contemplated by this Agreement, (c)&nbsp;the preparation and submission of any fling or notice required to be made or given in connection with any of the
transactions contemplated by this Agreement, and the obtaining of any Consent required to be obtained in connection with any of such transactions, and (d)&nbsp;the consummation of the Merger. Parent
and the Company agree that all such fees, costs and expenses are incurred solely for the benefit of Parent and the Company and, except as set forth in Section&nbsp;10.3(b) no such fee, cost or
expense shall be attributed to the officers, directors, employees, or shareholders of the Parent or the Company. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2>&nbsp;Notwithstanding the provisions of 10.3(a), fees incurred with respect to filings made pursuant to the HSR Act on
behalf of any shareholder of the Company with respect to the transactions contemplated in by this Agreement and (ii)&nbsp;any legal fees incurred by shareholders of the Company not incident to the
representation of the Company by its counsel, shall be borne and paid by such shareholder and not the Company or Parent. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;10.4&nbsp;&nbsp;Attorneys' Fees.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;If any action or proceeding relating to this Agreement or the enforcement of any
provision of this Agreement is brought against any party hereto, the prevailing party shall be entitled to recover reasonable attorneys' fees, costs and disbursements (in addition to any other relief
to which the prevailing party may be entitled). </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>38</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=4,SEQ=45,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=903464,FOLIO='38',FILE='DISK016:[01PAL5.01PAL2055]KO2055A.;4',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<A NAME="page_ko2055_1_39"> </A>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;10.5&nbsp;&nbsp;Notices.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Any notice or other communication required or permitted to be delivered to any party
under this Agreement shall be in writing and shall be deemed properly delivered, given and received when delivered (by hand, by registered mail, by courier or express delivery service or by facsimile)
to the address or facsimile telephone number set forth beneath the name of such party below (or to such other address or facsimile telephone number as such party shall have specified in a written
notice given to the other parties hereto): </FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE WIDTH="63%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TD WIDTH="94%"><FONT SIZE=2><B>if to Parent or Merger Sub:</B></FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD WIDTH="94%"><FONT SIZE=2><BR>
Inhale Therapeutic Systems,&nbsp;Inc.<BR>
150 Industrial Way<BR>
San Carlos, CA 94070<BR>
Attention: General Counsel<BR>
Facsimile: (650)&nbsp;631-3150</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD WIDTH="94%"><FONT SIZE=2><BR>
with a copy to:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD WIDTH="94%"><FONT SIZE=2><BR>
Cooley Godward llp<BR>
Five Palo Alto Square<BR>
3000 El Camino Real<BR>
Palo Alto, CA 94025<BR>
Attention: Mark P. Tanoury, Esq.<BR>
Facsimile: (650)&nbsp;849-7400</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD WIDTH="94%"><BR><FONT SIZE=2><B>if to the Company:</B></FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD WIDTH="94%"><FONT SIZE=2><BR>
Shearwater Corporation<BR>
1112 Church Street<BR>
Huntsville, AL 35801<BR>
Attention: J. Milton Harris<BR>
Facsimile: (256)&nbsp;533-4805</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD WIDTH="94%"><FONT SIZE=2><BR>
with a copy to:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD WIDTH="94%"><FONT SIZE=2><BR>
Bradley Arant Rose and White LLP<BR>
200 Clinton Ave, Suite 900<BR>
Huntsville, AL 35801<BR>
Attention: Scott Ludwig, Esq.<BR>
Facsimile: (256)&nbsp;517-5200</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD WIDTH="94%"><BR><FONT SIZE=2><B>if to the Shareholders' Agent:</B></FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD WIDTH="94%"><FONT SIZE=2><BR>
J. Milton Harris<BR>
3119 Highland Plaza<BR>
Huntsville, AL 35801<BR>
Facsimile: (256)&nbsp;553-4805</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD WIDTH="94%"><FONT SIZE=2><BR>
with a copy to:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD WIDTH="94%"><FONT SIZE=2><BR>
Bradley Arant Rose and White LLP<BR>
200 Clinton Ave, Suite 900<BR>
Huntsville, AL 35801<BR>
Attention: Scott Ludwig, Esq.<BR>
Facsimile: (256)&nbsp;517-5200</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;10.6&nbsp;&nbsp;Confidentiality.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Without limiting the generality of anything contained in Section&nbsp;5.4, on
and at all times after the Closing Date, the Signing Shareholders shall keep confidential, and shall not use </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>39</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=5,SEQ=46,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=437414,FOLIO='39',FILE='DISK016:[01PAL5.01PAL2055]KO2055A.;4',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<A NAME="page_ko2055_1_40"> </A>

<P><FONT SIZE=2>
or disclose to any other Person, any non-public document or other non-public information in the Signing Shareholders' possession that relates to the business of the Company or
Parent. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;10.7&nbsp;&nbsp;Time of the Essence.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Time is of the essence of this Agreement. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;10.8&nbsp;&nbsp;Headings.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;The underlined headings contained in this Agreement are for convenience of reference
only, shall not be deemed to be a part of this Agreement and shall not be referred to in connection with the construction or interpretation of this Agreement. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;10.9&nbsp;&nbsp;Counterparts.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;This Agreement may be executed in several counterparts, each of which shall
constitute an original and all of which, when taken together, shall constitute one agreement. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;10.10&nbsp;&nbsp;Governing Law.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;This Agreement shall be construed in accordance with, and governed in all respects
by, the internal laws of the State of California (without giving effect to principles of conflicts of laws). </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;10.11&nbsp;&nbsp;Successors and Assigns.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;This Agreement shall be binding upon: the Company and its successors and
assigns (if any); the Signing Shareholders and their respective personal representatives, executors, administrators, estates, heirs, successors and assigns (if any); Parent and its successors and
assigns (if any); and Merger Sub and its successors and assigns (if any). This Agreement shall inure to the benefit of: the Company; the Company's shareholders (to the extent set forth in
Section&nbsp;1.5); the holders of assumed Company Options (to the extent set forth in Section&nbsp;1.6); Parent; Merger Sub; the other Indemnitees (subject to Section&nbsp;9); and the respective
successors and assigns (if any) of the foregoing. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;10.12&nbsp;&nbsp;Specific Performance.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;The parties to this Agreement agree that, in the event of any breach or
threatened breach by any party to this Agreement of (i)&nbsp;any covenant, obligation or other provision set forth in this Agreement for the benefit of any other party to this Agreement prior to the
Closing or (ii)&nbsp;Section&nbsp;10.6 or Section&nbsp;8.3 herein at any time as such provisions shall be in effect, such other party shall be entitled (in addition to any other remedy that may
be available to it) to (a)&nbsp;a decree or order of specific performance or mandamus to enforce the observance and performance of such covenant, obligation or other provision, and (b)&nbsp;an
injunction restraining such breach or threatened breach. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;10.13&nbsp;&nbsp;Waiver.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;</FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2>&nbsp;No failure on the part of any Person to exercise any power, right, privilege or remedy under this Agreement, and no
delay on the part of any Person in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such power, right, privilege or remedy; and no single or partial
exercise of any such power, right, privilege or remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2>&nbsp;No Person shall be deemed to have waived any claim arising out of this Agreement, or any power, right, privilege or
remedy under this Agreement, unless the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered on behalf of such Person; and
any such waiver shall not be applicable or have any effect except in the specific instance in which it is given. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;10.14&nbsp;&nbsp;Amendments.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;This Agreement may not be amended, modified, altered or supplemented other than by
means of a written instrument duly executed and delivered on behalf of all of the parties hereto. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;10.15&nbsp;&nbsp;Severability.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;In the event that any provision of this Agreement, or the application of any such
provision to any Person or set of circumstances, shall be determined to be invalid, unlawful, void or unenforceable to any extent, the remainder of this Agreement, and the application of such
provision to Persons or circumstances other than those as to which it is determined to be invalid, unlawful, void </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>40</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=6,SEQ=47,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=272382,FOLIO='40',FILE='DISK016:[01PAL5.01PAL2055]KO2055A.;4',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<A NAME="page_ko2055_1_41"> </A>

<P><FONT SIZE=2>
or unenforceable, shall not be impaired or otherwise affected and shall continue to be valid and enforceable to the fullest extent permitted by law. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;10.16&nbsp;&nbsp;Parties in Interest.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Except for the provisions of Sections 1.5, 1.6 and 9, none of the provisions
of this Agreement is intended to provide any rights or remedies to any Person other than the parties hereto, the Company's shareholders, and their respective successors and assigns (if any). </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;10.17&nbsp;&nbsp;Entire Agreement.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;This Agreement sets forth the entire understanding of the parties hereto
relating to the subject matter hereof and thereof and supersede all prior agreements and understandings among or between any of the parties relating to the subject matter hereof; </FONT> <FONT SIZE=2><I>provided, however,</I></FONT><FONT SIZE=2> that
the Confidentiality Agreement executed by the Company on behalf of the Parent on March&nbsp;13, 2001 shall not be superseded
by this Agreement and shall remain in effect in accordance with its terms until the earlier of (a)&nbsp;the Effective Time, or (b)&nbsp;the date on which such Confidentiality Agreement is
terminated in accordance with its terms. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;10.18&nbsp;&nbsp;Construction.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;</FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2>&nbsp;For purposes of this Agreement, whenever the context requires: the singular number shall include the plural, and
vice versa; the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include the masculine
and feminine genders. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2>&nbsp;The parties hereto agree that any rule of construction to the effect that ambiguities are to be resolved against the
drafting party shall not be applied in the construction or interpretation of this Agreement. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(c)</B></FONT><FONT SIZE=2>&nbsp;As used in this Agreement, the words "include" and "including," and variations thereof, shall not be deemed to be
terms of limitation, but rather shall be deemed to be followed by the words "without limitation." </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(d)</B></FONT><FONT SIZE=2>&nbsp;Except as otherwise indicated, all references in this Agreement to "Sections" and "Exhibits" are intended to refer
to Sections of this Agreement and Exhibits to this Agreement. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>41</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=7,SEQ=48,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=319681,FOLIO='41',FILE='DISK016:[01PAL5.01PAL2055]KO2055A.;4',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->

<P><FONT SIZE=2><A
NAME="page_kq2055_1_42"> </A>
&nbsp;&nbsp;&nbsp;&nbsp;The parties hereto have caused this Agreement to be executed and delivered as of May&nbsp;22, 2001. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>42</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=49,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=560359,FOLIO='42',FILE='DISK016:[01PAL5.01PAL2055]KQ2055A.;11',USER='MWORTHY',CD='10-JUL-2001;14:54' -->
<A NAME="page_kq2055_1_43"> </A>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><BR><FONT SIZE=2><B>INHALE THERAPEUTIC SYSTEMS,&nbsp;INC.,</B></FONT><FONT SIZE=2><BR>
&nbsp;&nbsp;a Delaware corporation</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="45%"><FONT SIZE=2><BR>
/s/&nbsp;</FONT><FONT SIZE=2>AJIT S. GILL</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>
Its:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="45%"><FONT SIZE=2><BR>
President and Chief Executive Officer</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><BR><FONT SIZE=2><B>SQUARE ACQUISITION CORP.,</B></FONT><FONT SIZE=2><BR>
&nbsp;&nbsp;an Alabama corporation</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="45%"><FONT SIZE=2><BR>
/s/&nbsp;</FONT><FONT SIZE=2>AJIT S. GILL</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>
Its:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="45%"><FONT SIZE=2><BR>
Chairman and President</FONT><HR NOSHADE></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2>43</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=50,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=225795,FOLIO='43',FILE='DISK016:[01PAL5.01PAL2055]KQ2055A.;11',USER='MWORTHY',CD='10-JUL-2001;14:54' -->
<A NAME="page_kq2055_1_44"> </A>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><BR><FONT SIZE=2><B>SHEARWATER CORPORATION,</B></FONT><FONT SIZE=2><BR>
&nbsp;&nbsp;an Alabama corporation</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="45%"><FONT SIZE=2><BR>
/s/&nbsp;</FONT><FONT SIZE=2>J. MILTON HARRIS</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE><FONT SIZE=2> J. Milton Harris<BR>
As its: President</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><BR><FONT SIZE=2><B>DESIGNATED SHAREHOLDERS</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="45%"><FONT SIZE=2><BR>
/s/&nbsp;</FONT><FONT SIZE=2>J. MILTON HARRIS</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE><FONT SIZE=2> J. Milton Harris</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="45%"><FONT SIZE=2><BR>
Puffinus, L.P.<BR>
&nbsp;&nbsp;By: Puffinus,&nbsp;Inc.,<BR>
&nbsp;&nbsp;&nbsp;an Alabama corporation, in<BR>
&nbsp;&nbsp;&nbsp;its capacity as general partner<BR>
&nbsp;&nbsp;&nbsp;of Puffinus LP, a Delaware<BR>
&nbsp;&nbsp;&nbsp;limited partnership</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="45%"><FONT SIZE=2><BR>
/s/&nbsp;</FONT><FONT SIZE=2>J. MILTON HARRIS</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE><FONT SIZE=2> J. Milton Harris<BR>
As President of Puffinus,&nbsp;Inc.,<BR>
an Alabama corporation, in its<BR>
capacity as general<BR>
partner of Puffinus LP, a<BR>
Delaware limited partnership</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
<BR>
&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><BR>
<BR></FONT> <FONT SIZE=2><B>SHAREHOLDERS' AGENT</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="45%"><FONT SIZE=2><BR>
/s/&nbsp;</FONT><FONT SIZE=2>J. MILTON HARRIS</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE><FONT SIZE=2> J. Milton Harris</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2>44</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=3,SEQ=51,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=645602,FOLIO='44',FILE='DISK016:[01PAL5.01PAL2055]KQ2055A.;11',USER='MWORTHY',CD='10-JUL-2001;14:54' -->
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="page_ks2055_1_45"> </A> </FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="ks2055_exhibit_a_certain_definitions"> </A>
<A NAME="toc_ks2055_1"> </A>
<BR></FONT><FONT SIZE=2><B>Exhibit&nbsp;A<BR>  CERTAIN DEFINITIONS    <BR>  </B></FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;For purposes of the Agreement (including this Exhibit&nbsp;B): </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;Acquisition Transaction.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;"Acquisition Transaction" shall mean any transaction involving: </FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)</B></FONT><FONT SIZE=2>&nbsp;the sale, license, disposition or acquisition of all or a material portion of the Company's business or assets; </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)</B></FONT><FONT SIZE=2>&nbsp;the issuance, disposition or acquisition of (i)&nbsp;any capital stock or other equity security of the Company
(other than common stock issued to employees of the Company, upon exercise of Company Options or otherwise, in routine transactions in accordance with the Company's past practices), (ii)&nbsp;any
option, call, warrant or right (whether or not immediately exercisable) to acquire any capital stock or other equity security of the Company (other than stock options granted to employees of the
Company in routine transactions in accordance with the Company's past practices), or (iii)&nbsp;any security, instrument or obligation that is or may become convertible into or exchangeable for any
capital stock or other equity security of the Company; or </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(c)</B></FONT><FONT SIZE=2>&nbsp;any merger, consolidation, business combination, reorganization or similar transaction involving the Company. </FONT></P>

</UL>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;Agreement.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;"Agreement" shall mean the Agreement and Plan of Merger and Reorganization to which this Exhibit&nbsp;B is
attached (including the Disclosure Schedule), as it may be amended from time to time. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;Company Contract.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;"Company Contract" shall mean any Contract: (a)&nbsp;to which the Company is a party; (b)&nbsp;by
which the Company or any of its assets is bound or under which the Company has any obligation; or (c)&nbsp;under which the Company has any right or interest. </FONT></P>


<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;Company Proprietary Asset.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;"Company Proprietary Asset" shall mean any Proprietary Asset owned by or licensed to the
Company necessary for the operation of the Company's business as currently conducted. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;Consent.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;"Consent" shall mean any approval, consent, ratification, permission, waiver or authorization (including any
Governmental Authorization). </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;Contract.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;"Contract" shall mean any written, oral or other agreement, contract, subcontract, lease, understanding,
instrument, note, warranty, insurance policy, benefit plan or legally binding commitment or undertaking of any nature. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;Damages.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;"Damages" shall mean any loss, damage, injury, decline in value, lost opportunity, liability, claim, demand,
settlement, judgment, award, fine, penalty, Tax, or any out-of-pocket fees (including reasonable attorneys' fees), charges, costs (including costs of investigation) or expenses
of any nature. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;Disclosure Schedule.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;"Disclosure Schedule" shall mean the schedule (dated as of the date of the Agreement) delivered to
Parent on behalf of the Company and the Designated Shareholders. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;Encumbrance.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;"Encumbrance" shall mean any lien, pledge, hypothecation, charge, mortgage, security interest,
encumbrance, claim, infringement, interference, option, right of first refusal, preemptive right, community property interest or restriction of any nature (including any restriction on the voting of
any security, any restriction on the transfer of any security or other asset, any restriction on the receipt of any income derived from any asset, any restriction on the use of any asset and any
restriction on the possession, exercise or transfer of any other attribute of ownership of any asset). </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>45</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=52,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=1007865,FOLIO='45',FILE='DISK016:[01PAL5.01PAL2055]KS2055A.;5',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<A NAME="page_ks2055_1_46"> </A>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;Entity.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;"Entity" shall mean any corporation (including any non-profit corporation), general partnership,
limited partnership, limited liability partnership, joint venture, estate, trust, company (including any limited liability company or joint stock company), firm or other enterprise, association,
organization or entity. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;Environmental Law.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;"Environmental Law" means any federal, state, local or foreign Legal Requirement relating to
pollution or protection of human health from Materials of Environmental Concern (including ambient air, surface water, ground water, land surface or subsurface strata), including any law or regulation
relating to emissions, discharges, releases or threatened releases of Materials of
Environmental Concern, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Materials of Environmental Concern. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;Escrow Agent.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;"Escrow Agent" shall mean State Street Bank and Trust Company of California, N.A., or such other
financial institution as may be reasonably selected by Parent. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;Exchange Act.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;"Exchange Act" shall mean the Securities Exchange Act of 1934, as amended. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;Government Bid.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;"Government Bid" shall mean any quotation, bid or proposal submitted to any Governmental Body or any
proposed prime contractor or higher-tier subcontractor of any Governmental Body. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;Government Contract.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;"Government Contract" shall mean any prime contract, subcontract, letter contract, purchase order
or delivery order executed or submitted to or on behalf of any Governmental Body or any prime contractor or higher-tier subcontractor, or under which any Governmental Body or any such
prime contractor or subcontractor otherwise has or may acquire any right or interest. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;Governmental Authorization.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;"Governmental Authorization" shall mean any: (a)&nbsp;permit, license, certificate,
franchise, permission, clearance, registration, qualification or authorization issued, granted, given by or under the authority of any Governmental Body or pursuant to any Legal Requirement; or
(b)&nbsp;right under any Contract with any Governmental Body; provided, however that the term Government Authorizations shall not include Governmental Authorizations with respect to ownership of
Proprietary Assets. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;Governmental Body.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;"Governmental Body" shall mean any: (a)&nbsp;nation, state, commonwealth, province, territory,
county, municipality, district or other jurisdiction of any nature; (b)&nbsp;federal, state, local, municipal, foreign or other government; or (c)&nbsp;governmental or quasi-governmental authority
of any nature (including any governmental division, department, agency, commission, instrumentality, official, organization, unit, body or Entity and any court or other tribunal). </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;HSR Act.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;"HSR Act" shall mean the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. </FONT></P>


<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;Indemnitees.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;"Indemnitees" shall mean the following Persons: (a)&nbsp;Parent and its subsidiaries other than Merger
Sub; (b)&nbsp;Merger Sub; (c)&nbsp;the respective executive officers (as defined in Rule&nbsp;3b-7 of the Exchange Act) and directors of the Persons referred to in clauses "(a)" and
"(b)" above; and (d)&nbsp;the respective successors and assigns of the Persons referred to in clauses "(a)," "(b)" and "(c)" above; </FONT><FONT SIZE=2><I>provided, however</I></FONT><FONT SIZE=2>,
that the Designated Shareholders shall not be deemed to be "Indemnitees." </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;Knowledge.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;"Knowledge" shall mean (A)&nbsp;with respect to an individual (i)&nbsp;actual knowledge of such
individual, and (ii)&nbsp;that knowledge which a prudent business Person would have obtained in the management of such Person's business affairs after making reasonable due inquiry and exercising
reasonable due diligence; and (B)&nbsp;with respect to an Entity (i)&nbsp;actual knowledge of the officers and directors of such Entity, and (ii)&nbsp;that knowledge which a prudent business
Person in the position of </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>46</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=53,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=384968,FOLIO='46',FILE='DISK016:[01PAL5.01PAL2055]KS2055A.;5',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<A NAME="page_ks2055_1_47"> </A>

<P><FONT SIZE=2>
such an officer or director would have obtained in the management of such Person's business affairs after making reasonable due inquiry and exercising reasonable due diligence. </FONT></P>


<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;Legal Proceeding.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;"Legal Proceeding" shall mean any action, suit, litigation, arbitration, proceeding (including any
civil, criminal, administrative, investigative or appellate proceeding), hearing, inquiry, audit, examination or investigation commenced, brought, conducted or heard by or before, or otherwise
involving, any court or other Governmental Body or any arbitrator or arbitration panel. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;Legal Requirement.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;"Legal Requirement" shall mean any federal, state, local, municipal, foreign or other law, statute,
constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, regulation, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into
effect by or under the authority of any Governmental Body as the same are currently in effect and interpreted as of the date of this Agreement. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;Material Adverse Effect.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;An event, violation, inaccuracy, circumstance or other matter will be deemed to have a
"Material Adverse Effect" on an entity if such event, violation, inaccuracy, circumstance or other matter would have a material adverse effect on the business, condition, capitalization, assets,
liabilities, operations, or financial performance of such entity and its subsidiaries taken as a whole; provided, however, that none of the following shall be deemed, in and of itself, to have a
Material Adverse Effect on an entity: (A)&nbsp;an event, violation, inaccuracy, circumstance or that results from (1)&nbsp;conditions affecting the U.S. economy as a whole or any foreign economy
in any location where such entity has material operations or sales, or (2)&nbsp;conditions affecting the biotechnology industry so long as such conditions do not affect the entity in a
disproportionate manner as compared with companies of a similar size, (B)&nbsp;a delay in customer orders arising primarily out of or resulting primarily from the announcement of the transactions
contemplated by this Agreement, or (C)&nbsp;any failure by the entity to meet internal projections or forecasts or published revenue or earnings predictions. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;Materials of Environmental Concern.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;"Materials of Environmental Concern" shall mean chemicals, pollutants,
contaminants, wastes, toxic substances, petroleum and petroleum products and any other substance that are currently regulated by any Environmental Law. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;Parent Common Stock.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;"Parent Common Stock" shall mean common stock of Parent. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;Parent Stock Price.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;"Parent Stock Price" shall mean the average of the closing sales prices of a share of Parent Common
Stock as reported on the Nasdaq national market for each of the ten consecutive trading days preceding the date prior to Closing Date. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;Person.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;"Person" shall mean any individual, Entity or Governmental Body. </FONT></P>


<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;Proprietary Asset.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;"Proprietary Asset" shall mean any: (a)&nbsp;patent, patent application, trademark (whether
registered or unregistered), trademark application, trade name, fictitious business name, service mark (whether registered or unregistered), service mark application, copyright (whether registered or
unregistered), copyright application, maskwork, maskwork application, trade secret, know-how, customer list, franchise, computer software, computer program, invention, proprietary product,
technology, proprietary right or (b)&nbsp;right to use or exploit any of the foregoing. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;Representatives.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;"Representatives" shall mean officers, directors, employees, agents, attorneys, accountants, advisors
and representatives. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;SEC.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;"SEC" shall mean the United States Securities and Exchange Commission. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;Securities Act.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;"Securities Act" shall mean the Securities Act of 1933, as amended. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>47</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=3,SEQ=54,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=637986,FOLIO='47',FILE='DISK016:[01PAL5.01PAL2055]KS2055A.;5',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<A NAME="page_ks2055_1_48"> </A>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;Tax.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;"Tax" shall mean any tax (including any income tax, franchise tax, capital gains tax, gross receipts tax,
value-added tax, surtax, excise tax, ad valorem tax, transfer tax, stamp tax, sales tax, use tax, property tax, business tax, withholding tax or payroll tax), levy, assessment, tariff, duty (including
any customs duty), deficiency or fee, and any related charge or amount (including any fine, penalty or interest), imposed, assessed or collected by or under the authority of any Governmental Body. </FONT></P>

<P><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;Tax Return.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;"Tax Return" shall mean any return (including any information return), report, statement, declaration,
estimate, schedule, notice, notification, form, election, certificate or other document or information filed with or submitted to, or required to be filed with or submitted to, any Governmental Body
in connection with the determination, assessment, collection or payment of any Tax or in
connection with the administration, implementation or enforcement of or compliance with any Legal Requirement relating to any Tax. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>48</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=4,SEQ=55,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2",CHK=787460,FOLIO='48',FILE='DISK016:[01PAL5.01PAL2055]KS2055A.;5',USER='MWORTHY',CD='10-JUL-2001;13:40' -->
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<BR>
<P><br><A NAME="01PAL2055_2">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2><A HREF="#toc_kc2055_1">EXHIBIT 2.1</A></FONT><BR>
</UL>
<!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_ks2055_1">Exhibit A CERTAIN DEFINITIONS</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=DROCCON,SEQ=,EFW="2053544",CP="INHALE THERAPEUTIC SYSTEMS, INC",DN="2" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
